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ABSTRACT 
 
Design, Synthesis, and Evaluation of Dendrimers Based on Melamine as Drug Delivery 
Vehicles. (August 2007) 
Jong Doo Lim, B.S., Korea University;  
M.S., Korea University 
Chair of Advisory Committee: Dr. Eric E. Simanek 
 
A variety of dendrimers based on melamine are designed, synthesized, and 
evaluated for drug delivery systems. The synthesis of a dendrimer, including multiple 
copies of four orthogonally reactive groups, is described.  The three groups on the 
surface are nucleophilic and include four free hydroxyl groups, four tert-
butyldiphenylsilyl (TBDPS) ether groups, and sixteen amines masked as tert-
butoxycarbonyl (BOC) groups. The core of the dendrimer displays two electrophilic 
monochlorotriazines. The dendrimer above is further manipulated for in vivo 
biodistribution: incorporation of the reporting groups Bolton-Hunter and DOTA 
(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid); PEGylation for 
biocompatibility and size tuning. In preliminary biodistribution studies, dendrimers 
circulate in the blood for a longer time as the molecular weight increases, which is 
important to passively target tumor tissues via the EPR effect. Also, high uptake by the 
tumor tissues was observed in mice bearing prostate cancer xenografts.  
A drug delivery vehicle for the anticancer agent paclitaxel is described. This drug 
delivery vehicle contains sixteen molecules of paclitaxel via acid-labile ester linkage, 
 iv
two Bolton-Hunter groups, and sixteen monochlorotriazine groups for PEGylation. The 
in vitro drug release studies shows faster release of paclitaxel at lower pH in PBS. 
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 CHAPTER I 
INTRODUCTION 
 
The unique properties of dendrimers, which are rarely found in conventional 
polymers, have captured the intense attention of many researchers over decades: 
multivalency, a well-defined globular structure, mono or low polydispersity, large 
internal space for host-guest interactions, and availability of multiple functionalities. 
Due to such properties, dendrimers have been investigated for a variety of applications 
such as catalysis, medical diagnostics, sequestration of small molecules, and drug 
delivery.1-15 In this study we focus on the development of potent drug delivery vehicles, 
exploring dendrimers based on 1,3,5-triazine building blocks. 
 
Dendrimers: Concepts, Types, and Syntheses  
The term dendrimer was originated from the Greek dendron (tree or branch) and 
meros (part) by the analogy of its structure. The dendritic structure is composed of a core, 
an interior shell, and a multivalent periphery. The core and interior shell is well 
protected from the surroundings by the periphery, providing microenvironments to 
encapsulate guest molecules, such as hydrophobic drugs and catalysts. The multivalent 
periphery is very useful to introduce synthetic or biological entities to the polymeric 
system for diverse purposes.  
_________________________ 
This dissertation follows the style and format of Journal of the American Chemical Society. 
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Figure 1.1. Divergent and convergent synthetic routes to dendrimers.16 
 
Though the highly branched globular polymer seems woven and complicated, it 
actually displays symmetrical and repetitive architecture, which can be stepwise 
constructed by reiterative reactions with functional monomers. The synthesis of 
dendrimers is conducted in two different ways, either divergently or convergently 
(Figure 1.1). In the divergent synthesis,17 dendrimers are synthesized from the core to 
the surface step by step. Polypropylene imines (PPI) and polyamidoamines (PAMAM) 
are well-known and commercially available dendrimers synthesized in this route. On the 
other hand, in the convergent approach18 developed by Frechét et al., the dendrimer is 
synthesized from the surface as the starting point and ended up at the core. Generally, 
the convergent synthetic approach facilitates purification process due to the smaller 
2
 number of the reactive sites as well as the incorporation of multiple functional groups on 
the periphery, while the divergent approach is useful for the synthesis of high generation 
dendrimers and large-scale synthesis. 
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Figure 1.2. Architecture of dendrimers: (a) PPI; (b) PAMAM; (c) polyester; (d) triazine-
based dendrimer. 
 
3
 Figure 1.2 shows the dendritic architecture broadly being used for diverse 
applications. PPI structures developed mainly by Vögtle and Meijer19,20 can be 
constructed by Michael addition of 1,4-diaminobutane to acrylonitrile and the 
subsequent reduction of the nitriles to primary amines. The iterative reaction process can 
be repeated to produce higher generation dendrimers. Howerver, more defects and 
higher polydispersity are often observed in the synthesis of high generation PPI due to a 
large number of reactive sites on the surface. 
Tomalia’s PAMAM dendrimers21-23 have been most widely investigated and 
commercially available. PAMAM can be prepared from a diamine by divergent growth 
(Scheme 1.1). The first intermediate, star PAMAM (CO2Me)4, is synthesized from 
Michael addition of 1,2-diaminoethane to methyl acrylate. The reaction of the resulting 
intermedicate with the excess of 1,2-diaminoethane gives the tetraamine-terminated 
PAMAM. The iterative reactions are needed to produce higher generation PAMAM 
dendrimers. 
The bow-tie design by Gillies and Fréchet is based on polyesters.24,25 Two polyester 
dendrons are covalently linked. One dendron has free hydroxyl groups for the 
attachment of poly(ethylene oxide) (PEO) and the other dendron has acetal protecting 
groups for further manipulation such as drug conjugation and radiolabeling. Another 
Fréchet-type dendrimer is based on polyethers and prepared by convergent growth 
(Scheme 1.1). The polyether dendrimers that derive from the 3,5-dihydroxybenzyl 
alcohol group have been investigated for diverse purposes: self-assembling, catalysis, 
light harvest, and encapsulation.26-31 
4
 Scheme 1.1. Synthesis of dendrimers: (a) G2 PAMAM by a divergent route and (b) G2 
polyether by a convergent route 
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 The 1,3,5-triazines broadly used for preparation of herbicides are also employed to 
the synthesis of dendrimers.32-50 The advantages of triazine dendrimers mainly derive 
from their synthetic versatility. Chlorines on the triazine ring can be stepwise substituted 
with various nucleophiles via the mechanism of nucleophilic aromatic substitution. The 
differential reactivity of triazine chlorides on nucleophiles can be further regulated with 
reaction temperature.33 For instance, dichlorotriazines can be obtained from the reaction 
of cyanuric chloride (C3N3Cl3) with a nucleophilic amine (RNH2) at low temperature. 
Subsequent reaction with another amine (R’NH2) at room temperature can afford 
monochlorotriazines. The excess amount of amines or high reaction temperature is often 
required to substitute the chlorine of monochlorotriazine. Thus, the differential reactivity 
of chlorotriazine derivatives allows us to prepare compositionally diverse dendrimers 
with high purity and simplicity.34,35 
 
N N
N ClCl
Cl
N N
N ClRHN
Cl
N N
N NHR'RHN
Cl
N N
N NHR'RHN
NHR''
NH2R NH2R' NH2R''
0 oC rt
 
 
Mackay and Simanek33 demonstrated the chemoselective reactivity of a variety of 
amines with a monochlorotriazine. The 2-chloro-4,6-dimorpholino-1,3,5-triazine was 
used to conduct the competition reactions. Figure 1.3 shows relative substitution rates in 
the competition reactions of various amines with the monochlorotriazine. 
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Figure 1.3. Relative reactivity of various amines for the substitution of a 
monochlorotriazine.33 
 
The chemoselective reactivity of triazine chlorides and amine nucleophiles gives a 
variety of benefits for the synthesis of dendrimers, including multi-functional groups on 
the surface, single-pot synthesis, precise control on the dendritic composition and 
structure, and facile postsynthetic manipulation. 
 
 
Figure 1.4. Polymeric architectures for therapeutics. 
7
 Drug Delivery Vehicles  
Polymeric architecture including stars, grafts, dendronized polymers, and 
dendrimers has been explored to develop delivery-vehicles for therapeutic agents (Figure 
1.4).10,13,14,51-57 Globular multi-functional dendrimers are more versatile as drug-carriers, 
compared to linear mono-functional polymers. However, such dendrimers are often 
challengeable to synthesize and hardly available in the market. As a result, most of drug-
polymer conjugates in clinical trials were prepared by using linear or graft polymers 
(Table 1.1).14,58 
 
Table 1.1. Drug-polymer conjugates and micelles in clinical trials. 
Compound Linker Status of development
doxorubicin-HPMA copolymer (PK1) amide phase II 
galactosamine-doxorubicin-HPMA copolymer (PK2) amide phase I/II 
doxorubicin-aspartic acid-PEG micelle (NK911) amide/free drug phase I 
paclitaxel-HPMA copolymer (PNU166945) ester phase I 
paclitaxel-polyglutamate (CT2103) ester phase II/III 
camptothecin-PEG (Prothecan) alanine ester phase II 
camptothecin-polyglutamate (CT2106) ester phase I 
diamineplatinum (II) HPMA copolymer (AP5280) amide phase I 
 
 
Many drugs have obstacles to be directly used in clinical therapy due to low 
solubility in physiological conditions, instability, low biopermeability, or systemic 
toxicity. Synthetic/biopolymers have promising characteristics to become efficient drug-
8
 carriers, overcoming such challenges. For example, hydrophilic polymers can be linked 
to the drug to improve the solubility in aqueous media. Conjugation and encapsulation 
using polymers are a useful way to shield the drugs from the environment before 
released at the target area and to reduce toxicity during delivery. Also, cell-penetrating 
peptides can be employed to the drug-carriers to improve biopermeability. 
 
 
Dendrimer-drug
Endosome LysosomeH+
H+
H+
 
 
 
 
 
Figure 1.5. Polymer-drug conjugates to passively target tumor tissues via EPR effect 
and cellular uptake by endocytic internalization.14,16 
 
 
Healthy tissue
Tumor tissue
9
 Another important advantage of polymer-drug conjugates comes from molecular 
sizes. Maeda and coworkers59,60 reported that large macromolecules had a passive 
selectivity for various types of tumors due to a leaky angiogenic tumor vasculature and 
the lack of lymphatic drainage, which was termed the enhanced permeability and 
retention time (EPR) effect (Figure 1.5). Typically, the defective pores of the tumor 
vasculature show the range of size 200 to 600 nm.61 By tailoring the size of drugs (over 
80% of marketed drugs are smaller than MW 500 Da) with polymers, the drug-polymer 
conjugates (> 20 kDa) may be efficiently accumulated on the tumor cells with prolonged 
circulation time in blood, and then internalized into the cell by endocytosis.62,63 
 
solubilizing group
reporting group
drug
cleavable linker
recepter on diseased cell
targeting group
 
Figure 1.6. The design of drug delivery system using dendrimers. 
10
 In order to design efficient drug delivery system, we need to consider the followings 
(Figure 1.6): biocompatibility (nontoxic, nonimmunogenic, and soluble in physiological 
conditions), targeting groups, drug loading capacity with controlled release, and 
reporting tags (radio or fluorescent tags). Dendrimers containing a large number of 
reactive sites and multiple functional groups are advantageous to incorporate all these 
molecules of interest. 
Recent toxicity studies of cationic (amino-terminated) and anionic (carboxylate-
terminated) PAMAM dendrimers have revealed that cationic polymers have a 
significantly higher cytotoxicity on various cell lines.64-67 The high toxicity of cationic 
dendrimers is explained by strong interaction between the cationic dendrimer and the 
negatively charged cell membrane, causing cell lysis. Also, less flexible and globular 
dendrimers show lower cytotoxicity compared with flexible and linear dendrimers, 
which can be explained by weaker adherence to cellular surfaces due to less flexibility of 
globular structures.16,68,69 Cytotoxicity studies with dendimers based on melamine were 
performed by Chen and Simanek et al.37,44 As outlined in Figure 1.7, the library of 
dendrimers comprised of 1-2 (cationic), 3-5 (anionic), and 6 (neutral). While the cationic 
dendrimers 1 and 2 showed significant cytotoxicity even at low concentrations (< 0.01 
mg/mL), the anionic 3, 4 and 5 showed little cytotoxicity at the same concentrations. The 
PEGylated dendrimer 6 displayed little cytotoxicity even at high concentrations (0.1-10 
mg/mL). Thus, the conjugation of terminal amine groups with PEG chains enhanced 
biocompatibility of triazine-based dendrimers. 
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Figure 1.7. A library of dendrimers based on melamine used in cytotoxicity studies. 
 
Two strategies are employed to dendritic drug delivery: encapsulation and 
conjugation. In research on drug encapsulation by Kono et al.,70,71 PAMAM dendrimers 
based on ethylenediamine are used to encapsulate the anticancer drugs, doxorubicin and 
methotrexate. The acid-base interactions between the drugs and the basic hydrophobic 
interior of PAMAM dendrimers afforded the high capacity of drug loading and slow 
release. However, the controlled release of drugs would be a hard problem to solve, 
since the encapsulation and release of drugs by dendrimers are highly dependable on the 
structures and compositions of drugs and dendrimers. The alternative drug-dendrimer 
conjugation will take more advantages of regulating the loading and release of drugs by 
using desirable linkers. A variety of degradable linkages have been used for drug-
12
 delivery vehicles including acid-labile bonds,72-79 disulfide,80-82 and enzyme-cleavable 
bonds83-85 (Figure 1.8). 
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Figure 1.8. Drug-polymer conjugates with a variety of linkers: (a) 5-fluoro-2’-
deoxyuridine-polymer conjugate with acetal linkage; (b) FA-MTX-PAMAM conjugate; 
(c) poly(RCOOH-co-BA-co-PDSA)-drug conjugate; (d) doxorubicin-HPMA conjugate. 
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 Acid labile linkers such as ester, acetal, and hydrazone have been extensively used 
for drug conjugation, as the drug release can be triggered at the acidic environment (pH 
6.5~4.0) of endosome and lysosome during endocytosis. Figure 1.8 (a) shows the 
anticancer agent 5-fluoro-2’-deoxyuridine that is conjugated to linear PEG via an acetal 
linker.75 Hydrolysis study of the drug-conjugate at pH 5.0 displayed over 90% release of 
the drug after 10 min incubation at 37 oC. Baker and coworkers77 reported a drug-
delivery vehicle based on G5 amine-terminated PAMAM dendrimers (Figure 1.8 (b)). 
Folic acid (FA) was conjugated to the terminal amines as targeting ligands, and the 
residue of cationic amines were masked by using glycidol to reduce toxicity. The 
anticancer drug methotrexate (MTX) was then conjugated via ester linkage. The MTX-
conjugates with FA effectively killed receptor-expressing cells by receptor-mediated 
endocytosis. 
 Recent studies have showed that glutathione (GSH), L-γ-glutamyl-L-
cysteinylglycine, is significantly overexpressed in tumor cells of various regions such as 
breast, lung, ovary, bone marrow, and colon, as compared with the adjacent normal 
cells.86,87 The high level of GSH in many cancer tissues allows us to control drug 
delivery in more efficient manner by using thiol-disulfide exchange. As shown in Figure 
1.8 (c), Hoffman and Stayton et. al.82 designed pH-responsive and membrane-
destabilizing polymers with glutathione-reactive disulfide bonds. The polymer 
conjugates comprise of three components: pH responsive groups (alkyl acrylic acid 
monomers), hydrophobic groups (butyl acrylate monomers), and drug carrier groups 
(pyridyl disulfide acrylate (PDSA) monomers). The polymers are ionized and 
14
 hydrophilic at physiological pH, but they become more hydrophobic in acidic endosome, 
disrupting the membrane to be released into the cytoplasm. Glutathione in the cytosol 
can accelerate the drug release by reducing the disulfide bond of the conjugates. 
Also, Gly-Phe-Leu-Gly peptidyl linkers have been used for the enzymatic cleavage 
by the lysosomal protease cathepsin B in endocytosis.83 The doxorubicin-HPMA 
copolymer conjugate (PK1) was the first member of the drug-polymer conjugates in 
clinical trials (Figure 1.8 (d)). N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer 
extensively used for polymer therapeutics was conjugated to the anticancer drug 
doxorubicin (about 8 wt%) by using the tetrapeptidyl linker. In phase I evaluation, the 
maximum tolerated dose (MTD) of PK1 was 320 mg/m2 doxorubicin equivalents, which 
was a fivefold increase relative to free doxorubicin.58,88,89 
In the following chapters, the design and synthesis of dendrimers with orthogonal 
functional groups are discussed, and followed by post-synthetic manipulations and in 
vivo biodistribution studies. A drug delivery vehicle for the anticancer drug paclitaxel is 
also addressed. 
15
 CHAPTER II 
SYNTHESIS OF A DENDRIMER WITH FOUR ORTHOGONALLY REACTIVE 
GROUPS∗ 
 
Introduction 
We, and the drug-delivery community, have been intrigued by dendrimers for use as 
drug delivery vehicles.10-14 These highly branched, globular macromolecules present 
well-defined (often uniquely monodisperse) structures, a large number of reactive 
surface groups, and may afford passive selectivity for tumors based on the enhanced 
permeability and retention time (EPR) effect.59 Much of the molecular details for 
optimizing these vehicles to function in the complex environment presented by an 
organisms is poorly understood, but advances are being made by numerous investigators 
each favoring a specific subclass of dendrimers including polyesters,24 
poly(amidoamines),79 poly(propylene imines),90 and poly(amides).91 We favor triazines 
linked by diamines.32-45 The systematic replacement of chlorine atoms around the 
triazine ring of cyanuric chloride offers tremendous potential for compositional diversity 
and a hydrophobic interior for sequestering hydrophobic drugs. 
Here, we employ control over composition to synthesize a dendrimer with four 
different groups of reactive sites. We envision that these sites will be used for  
_________________________ 
∗Reproduced in part with permission from “Toward the next-generation drug delivery vehicle: 
Synthesis of a dendrimer with four orthogonally reactive groups” by Jongdoo Lim and Eric E. 
Simanek. Mol. Pharm. 2005, 2, 273-277. Copyright 2005 American Chemical Society. 
16
 i) conjugating drugs, ii) enhancing solubility and biocompatibility (PEGylation), iii) 
presenting biodistribution tags, and iv) displaying targeting ligands. 
In our previous studies, we reported the synthesis of versatile dendrimer with five 
different functional groups, including free hydroxyls, levulinic acid esters, tert-
butyldiphenylsilyl (TBDPS) ethers, pyridyl disulfide (PyrSSR) groups, and tert-
butyloxycarbonate (BOC) protected amines.34  The choice of these groups derived from 
Wong's orthogonally-protected sugars.92 This original, orthogonally reactive dendrimer, 
however, suffered from three issues that limited its potential role as a building block for 
manipulation. First, the levulinic acid ester groups and the pyridyldisulfides were not as 
chemically robust as the other protecting groups during the dendrimer synthesis. 
Accordingly, yields for reactions involving these groups were lower (~80%) compared 
with manipulations of the intermediate containing the other groups (>95%). Second, the 
dendrimer was more complex than necessary; only four unique groups of sites are 
believed to be required. Third, too many of the orthogonal groups were hydroxyl groups 
which are less reactive and less selective than the electrophilic triazines incorporated 
here. Here we describe a dendrimer, 1, with four groups that are amenable for post-
synthetic manipulation (Figure 2.1) that incorporates both nucleophilic and electrophilic 
sites. We envision that this dendrimer will serve as the basis for future studies of 
biodistribution and efficacy in tumor-bearing animals. 
17
 N
N
N
N
HN
N
N
N N
NH
NH
N
N
N
N
N
NH
(BOCNHCH2CH2CH2)2N
OHO
N
N
N
NH
(BOCNHCH2CH2CH2)2N
OTBDPSO
HN
NH
N
N
N N
NH
HN
N
N
N
N
N
NH
(BOCNHCH2CH2CH2)2N
OHO
N
N
N
NH
(BOCNHCH2CH2CH2)2N
OTBDPSO
N
N
N N
Cl 2
(NHBOC)16(TBDPSO)4
(OH)4
(Cl)2
1
 
Figure 2.1. Dendrimer 1 in atomic and schematic detail. 
 
 
Results and Discussion 
Dendrimer 1 was synthesized using a strategy similar to that of the original 
dendrimer described by our group.34 This new dendrimer has a total of twenty-six 
reactive sites for manipulation. This architecture represents the current generation of 
dendrimers that we are exploring for drug delivery. Such a vehicle will carry a cargo of 
drugs linked by biolabile, covalent bonds, ligands for targeting, poly(ethylene glycol) (or 
PEG) for biocompatibility and tuning size which in turn affects circulation time and 
excretion route, and a beacon that indicates location. The hydroxyl groups are subject to 
acylation directly, or upon cleavage of the silyl ethers with tetrabutylammonium fluoride 
(TBAF) for further manipulation. The BOC groups can be unmasked to provide amines 
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 amenable to multiple manipulation strategies. All three of these groups were present in 
the previous generation vehicle.  However, here the levulinic esters and pyridyl 
disulfide groups have been replaced with monochlorotriazines. These groups react 
efficiently with amine nucleophiles:  we have invested significant energies in the study 
of such groups and find that cyclic secondary amines are well suited to for this 
reaction.33  
The synthesis of dendrimer 1 is outlined in Scheme 2.1 and employs the convergent 
strategy18 in which the surface groups are elaborated iteratively toward the core group. 
Intermediate 2 is prepared by protecting the primary amines of 3,3’-
diaminodipropylamine with BOC-ON.93 Subsequent reactions with cyanuric chloride 
and 2-(2-aminoethoxy)ethanol respectively will produce monochlorotriazine 3, which 
can selectively react with the secondary amine of 4-(aminomethyl)piperidine (4-AMP) 
to yield 5. Using TBDPSCl, the free hydroxyl group of 3 is protected to afford 4, and 
then reacted with 4-AMP to give 6. The synthesis of 7 is conducted in a single-pot 
reaction by first reacting 6 with cyanuric chloride. The reaction is followed by adding 5 
and then completed with the addition of 4-AMP. In a similar way, intermediate 7 is 
sequentially reacted with cyanuric chloride and then 4-AMP to give 8. Dendrimer 1 was 
prepared in two steps from 8 through the intermediate dichlorotriazine 9 and subsequent 
dimerization with piperazine. The synthesis is executed in seven linear (8 total) steps 
from 2 to give the target dendrimer in 55% overall yield from the protected triamine. 
The route as described can be used to prepare moderate quantities of material. For 
example, intermediate 8 is useful for this dendrimer and related structures: it has been 
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 prepared on 20 g scale. This effort takes between 7 and 8 days at this scale. The final 
dendrimer has been prepared on 6g scale. 
 
 
Scheme 2.1. Synthesis of 1a 
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a Reagents and conditions: (a) cyanuric chloride, DIPEA, THF, 0 oC, 2h; then 2-(2-
aminoethoxy)ethanol with CH3OH, rt, 24h; (b) TBDPS-Cl, imidazole, DIPEA, THF, rt, 
4h; (c) 4-(aminomethyl)piperidine, THF, rt, 8h; (d) cyanuric chloride, DIPEA, THF, 0 
oC, 2h; then 5, rt, 24h; then 4-(aminomethyl)piperidine, 24h; (e) cyanuric chloride, 
DIPEA, THF, rt, 48h; then 4-(aminomethyl)piperidine, rt, 24h; (f) cyanuric chloride, 
DIPEA, THF, 0 oC, 5h; (g) piperazine, DIPEA, THF:CH3OH=7:1, 0 oC to rt, 48h. 
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 The synthesis is followed by mass spectrometry and NMR spectroscopy. Mass 
spectrometry is particularly valuable (Figure 2.2). With rare exception, the reaction 
proceeds spot-to-spot conversion as judged by thin layer chromatography and yields 
products that appear to be single compounds after chromatography. The mass spectra 
show lines corresponding to the the protonated material and sodium and potassium ion 
adducts. Ladders of lines corresponding to loss of BOC groups that occur presumably 
during the ionization process are often observed for larger species.  Doubly charged 
species are observed in the spectrogram of 1, which are isotopically resolved adducts 
with H+, Na+, and K+ as well as fragment peaks corresponding to loss of one and two 
BOC groups. 
NMR spectroscopy also is diagnostic for the reactions, but interpretation is 
hampered by opportunities for the existence of slowly interconverting rotamers derived 
from hindered rotation about the triazine-NHR bond. These rotamers manifest 
themselves as broad lines in the proton NMR traces and often as double-lines in the 13C 
NMR traces. Replacement of the chlorine atoms of monochlorotriazines with 4-
(aminomethyl)piperidine typically simplifies the spectrum due presumably to either the 
reduction of rotamer number or the dissipation in the magnitude of the C-Cl dipole. 
21
  
 
Figure 2.2. Mass spectrograms of 2-9, and 1 acquired by ESI-TOF or MALDI-TOF MS. 
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 Conclusions 
We have prepared a versatile dendrimer with four orthogonally reactive groups: 
monochlorotriazine, free hydroxyl, TBDPS and BOC groups. Each of the functional 
surface groups can be readily utilized to improve solubility in physiological conditions, 
load drugs, link ligands or antibodies for targeting specific diseased cells and attach 
imaging agent for biodistribution assay. All of the synthetic steps are well established to 
afford the moderate scale preparation of the target. 
 
Experimental 
General Procedures 
Chemicals were purchased from Aldrich and Acros and used without further 
purification. All solvents were ACS grade and used without further purification.  NMR 
spectra were recorded on a Varian Mercury 300 MHz or Inova 500 MHz spectrometer in 
CDCl3, MeOH-d4, or CDCl3:MeOH-d4 (10:1). All mass spectral analyses were carried 
out by the Laboratory for Biological Mass Spectrometry at Texas A&M.     
Experimental Procedures 
Intermediate 2. A solution of BOC-ON (30.0 g, 122 mmol) in THF (150 mL) was 
added dropwise to an ice-bath cooled solution of 3,3’-diaminodipropylamine (8.5 mL, 
60.9 mmol) and DIPEA (30mL, 172 mmol) in THF (150 mL). After the addition was 
complete, the reaction mixture was stirred for 4 h at room temperature, and the solvent 
was then removed by reduced-pressure evaporation. The residue was dissolved in 
dichloromethane and extracted with 5% NaOH (aq). The organic layer was dried over 
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 MgSO4 and then evaporated under vacuum. The resulting thick oil was precipitated from 
dichloromethane and petroleum ether to give 2 (17.1 g, 85%) as a white solid. 1H NMR 
(300 MHz, CDCl3) δ 3.21 (q, 4H), 2.66 (t, J = 6.5 Hz, 4H), 1.66 (m, 4H), 1.44 (s, 18H); 
13C NMR (75 MHz, CDCl3) δ 156.26, 79.13, 47.54, 39.05, 29.86, 28.55; MS (ESI-TOF) 
calcd for C16H33N3O4 331.25, found 332.27 (M+H)+.  
Intermediate 3. A reaction solution of 2 (5.0 g, 15.1 mmol) and DIPEA (8.0 mL, 
46.0 mmol) in THF (150 mL) was cooled in a salt/ice-bath before cyanuric chloride 
(2.78 g, 15.1 mmol) was added. The solution was stirred for 2 h at low temperature.  
Subsequently, 2-(2-aminoethoxy)ethanol (3.0 mL, 30.0 mmol) and methanol (25 mL) 
were added to the reaction mixture. The reaction solution was stirred for 24 h.  
Following removal of the salts by filtration, the solution was evaporated under vacuum. 
The residue was dissolved in dichloromethane and washed with brine. The organic layer 
was dried over MgSO4 and then evaporated under vacuum. The crude product was 
purified by silica gel chromatography (ethyl acetate:hexane = 3:1) to afford 3 (7.8 g, 
93%). 1H NMR (300 MHz, CDCl3) δ 3.71 (br m, 2H), 3.62-3.47 (m, 10H), 3.07 (br m, 
4H), 1.71 (m, 4H), 1.42 (s, 18H); 13C NMR (75 MHz, CDCl3) δ 168.73, 165.46, 165.12, 
156.29, 156.08, 79.40, 78.98, 72.54, 69.58, 69.38, 61.70, 44.14, 43.68, 41.17, 40.84, 
38.38, 37.76, 36.95, 28.52, 28.25, 28.00, 27.88; MS (ESI-TOF) calcd for C23H42ClN7O6 
547.29, found 548.31 (M+H)+. 
Intermediate 4. A solution of 3 (2.5 g, 4.6 mmol), TBDPS-Cl (1.4 mL, 5.3 mmol), 
imidazole (250 mg, 3.7 mmol), and DIPEA (0.90 mL, 5.2 mL) in THF (50 mL) was 
stirred for 4 h at room temperature and the solvent was then removed by reduced-
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 pressure evaporation. The residue was dissolved in dichloromethane, washed with brine, 
dried over MgSO4 and evaporated under vacuum. The crude compound was purified by 
silica gel chromatography (ethyl acetate:hexane = 1:1) to give 4 (3.4 g, 94%) as a white 
solid. 1H NMR (300 MHz, CDCl3) δ 7.67 (m, 4H), 7.40 (m, 6H), 3.79 (m, 2H), 3.62-
3.46 (m, 10H), 3.07 (br m, 4H), 1.73 (m, 4H), 1.44 (s, 9H), 1.42 (s, 9H), 1.05 (s, 9H); 
13C NMR (75 MHz, CDCl3) δ 168.93, 165.50, 165.26, 156.31, 156.02, 135.68, 133.62, 
129.81, 127.80, 79.34, 78.98, 72.52, 72.34, 69.84, 69.52, 63.50, 43.85, 43.51, 41.00, 
37.55, 36.90, 28.56, 27.96, 27.79, 26.92, 26.68, 19.29; MS (MALDI-TOF) calcd for 
C39H60ClN7O6Si 785.41, found 786.44 (M+H)+. 
Intermediate 5. Intermediate 3 (2.9 g, 5.3 mmol) was dissolved in THF (50 mL) 
and 4-aminomethyl piperidine (2.0 mL, 16.6 mmol) was added. The solution was stirred 
for 8 h at room temperature and then evaporated under vacuum. The residue was 
dissolved in dichloromethane, washed with brine, dried over MgSO4, and evaporated 
under vacuum. The product was purified by silica gel chromatography 
(dichloromethane:methanol = 7:1 with 1% NH4OH) to give 5 (3.2 g, 97%) as a white 
solid. 1H NMR (300 MHz, CDCl3) δ 4.69 (br, 2H), 3.69 (t, J = 4.5 Hz, 2H), 3.58-3.55 (m, 
10H), 3.02 (br s, 4H), 2.75 (t, J = 12.2, 2H) 2.57 (d, J = 6.3 Hz, 2H), 1.75-1.65 (m, 6H), 
1.54 (br, 1H), 1.40 (s, 18H), 1.09 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 165.96, 165.46, 
164.58, 155.99, 78.83, 72.37, 69.97, 61.34, 47.71, 43.16, 42.11, 40.47, 39.44, 38.35, 
37.03, 29.67, 28.44, 27.67; MS (MALDI-TOF) calcd for C29H55N9O6 625.43, found 
626.59 (M+H)+. 
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 Intermediate 6. Intermediate 4 (3.0 g, 3.84 mmol) was dissolved in THF (50 mL) 
and 4-aminomethyl piperidine (1.4 mL, 11.6 mmol) was added. The solution was stirred 
for 8 h at room temperature and then evaporated under vacuum. The residue was 
dissolved in dichloromethane, washed with brine, dried over MgSO4, and evaporated 
under vacuum. The product was purified by silica gel chromatography 
(dichloromethane:methanol = 7:1 with 1% NH4OH) to give 6 (3.1 g, 93%) as a white 
solid. 1H NMR (500 MHz, CDCl3) δ 7.68 (m, 4H), 7.39 (m, 6H), 4.73 (br, 2H), 3.79 (t, J 
= 5.3 Hz, 2H), 3.60-3.56 (m, 10H), 3.04 (br s, 4H), 2.77 (t, J = 11.3, 2H) 2.60 (d, J = 6.5 
Hz, 2H), 1.76-1.69 (m, 6H), 1.55 (br, 1H), 1.42 (s, 18H), 1.11 (m, 2H), 1.04 (s, 9H); 13C 
NMR (125 MHz, CDCl3) δ 166.12, 165.77, 164.86, 156.13, 135.69, 133.74, 129.72, 
127.75, 79.05, 72.35, 70.26, 63.50, 47.97, 43.32, 42.14, 40.73, 39.74, 37.28, 36.96, 
29.85, 28.61, 27.66, 27.04, 26.92, 26.79, 19.28; MS (MALDI-TOF) calcd for 
C45H73N9O6Si 863.55, found 864.54 (M+H)+. 
Intermediate 7. Cyanuric chloride (404 mg, 2.19 mmol) was added to an ice-bath 
cooled solution of 6 (1.893 g, 2.19 mmol) and DIPEA (1.4 mL, 8.0 mmol) in THF (50 
mL). The solution was stirred for 4 h at 0 oC before a THF solution (20 mL) of 5 (1.403 
g, 2.24 mmol) was added.  The solution was stirred for 24 h at room temperature. After 
the addition of 4-aminomethyl piperidine (3.0 mL, 25.0 mmol), the solution was stirred 
for an additional 24 h at room temperature and evaporated under vacuum. The residue 
was dissolved in dichloromethane, washed with brine, dried over MgSO4, and 
evaporated under vacuum. The crude product was purified by silica gel chromatography 
(dichloromethane:methanol = 7:1 with 1% NH4OH) to give 7 (3.4 g, 92% ). 1H NMR 
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 (300 MHz, CDCl3) δ 7.67 (m, 4H), 7.38 (m, 6H), 4.72 (br, 6H), 3.79 (t, J = 5.1 Hz, 2H), 
3.73 (t, J = 4.4 Hz, 2H), 3.59-3.55 (m, 20H), 3.28 (br , 4H), 3.05 (br, 8H), 2.78-2.69 (br 
m, 8H), 1.77-1.70 (br m, 17H), 1.41 (s, 36H), 1.17 (m, 6H), 1.04 (s, 9H); 13C NMR (75 
MHz, CDCl3) δ 166.03, 165.78, 165.62, 164.86, 164.70, 156.15, 135.72, 133.77, 129.75, 
127.78, 79.08, 72.37, 70.29, 70.15, 63.51, 61.76, 47.50, 46.28, 46.19, 43.33, 43.26, 
42.43, 40.75, 38.90, 37.27, 30.03, 29.83, 28.63, 27.83, 26.95, 19.31; MS (MALDI-TOF) 
calcd for C83H139N23O12Si 1678.07, found 1679.27 (M+H)+. 
Intermediate 8. Cyanuric chloride (170 mg, 0.922 mmol) was added to a solution 
of 7 (3.139 g, 1.87 mmol) and DIPEA (0.6 mL, 3.4 mmol) in THF (80 mL).  The 
solution was stirred for 48 h at room temperature. After the addition of 4-aminomethyl 
piperidine (1.5 mL, 12.5 mmol), the solution was stirred for an additional 24 h, and then 
evaporated under vacuum. The residue was dissolved in dichloromethane, washed with 
brine, dried over MgSO4, and evaporated under vacuum. The product was purified by 
silica gel chromatography (dichloromethane:methanol = 7:1 with 1% NH4OH) to give 8 
(2.85 g, 87%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.67 (m, 8H), 7.37 (m, 
12H), 4.70 (br, 14H), 3.79 (t, J = 5.3 Hz, 4H), 3.72 (br , 4H), 3.58-3.55 (m, 40H), 3.26 
(br , 12H), 3.05 (br, 16H), 2.75 (br , 16H), 1.76-1.69 (br m, 37H), 1.41 (s, 72H), 1.16 (br, 
14H), 1.03 (s, 18H); 13C NMR (125 MHz, CDCl3) δ 165.83, 164.80, 156.14, 135.69, 
133.74, 129.73, 127.76, 79.05, 72.42, 72.35, 70.27, 70.13, 63.49, 61.66, 46.14, 43.31, 
43.24, 42.35, 40.73, 40.64, 37.20, 36.97, 30.01, 29.75, 28.62, 27.80, 26.93, 19.29; MS 
(MALDI-TOF) calcd for C175H289N51O24Si2 3545.25, found 3546.19 (M+H)+. 
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 Intermediate 9. Cyanuric chloride (62 mg, 0.336 mmol) was added to an ice-bath 
cooled solution of 8 (800 mg, 0.226 mmol) and DIPEA (174 μL, 1.0 mmol) in THF (20 
mL). The reaction solution was stirred for 5 h at 0 oC and then evaporated under vacuum. 
The residue was dissolved in dichloromethane, washed with brine, dried over MgSO4, 
and evaporated under vacuum. The crude product was purified by silica gel 
chromatography (ethyl acetate to dichloromethane:methanol = 8:1) to give 9 (690 mg, 
83%) as a white solid. 1H NMR (500 MHz, CDCl3) δ 7.67 (m, 8H), 7.36 (m, 12H), 4.68 
(br, 14H), 3.78 (t, J = 5.0 Hz, 4H), 3.70 (br , 4H), 3.57-3.54 (m, 40H), 3.24 (br , 14H), 
3.03 (br, 16H), 2.73 (br , 14H), 1.72-1.68 (br , 37H), 1.39 (s, 72H), 1.14 (br, 14H), 1.02 
(s, 18H); 13C NMR (125 MHz, CDCl3) δ 170.83, 166.02, 164.73, 156.07, 135.61, 133.65, 
129.66, 127.69, 78.96, 72.38, 72.26, 70.18, 63.42, 61.59, 46.78, 46.17, 43.20, 42.22, 
40.66, 40.55, 37.18, 36.88, 29.95, 29.59, 28.55, 27.72, 26.86, 19.21; MS (MALDI-TOF) 
calcd for C178H288Cl2N54O24Si2 3692.19, found 3693.14 (M+H)+. 
Dendrimer 1. A solution of piperazine (3.2 mg, 0.0371 mmol) and DIPEA (40 μL, 
0.232 mmol) in methanol (1 mL) was added dropwise to an ice-bath cooled solution of 9 
(300 mg, 0.0812 mmol) in THF (6 mL). The solution was warmed to room temperature, 
stirred for 48 hr, and then evaporated under vacuum. The residue was dissolved in 
dichloromethane, washed with brine, dried over MgSO4, and evaporated under vacuum. 
The crude product was purified by silica gel chromatography (ethyl acetate to 
dichloromethane:methanol = 8:1) to give 1 (233 mg, 85%) as a white solid. 1H NMR 
(500 MHz, CDCl3) δ 7.66 (m, 16H), 7.33 (m, 24H), 4.69 (br, 28H), 3.84 (br, 8H), 3.78 (t, 
J = 5.3 Hz, 8H), 3.71 (br , 8H), 3.58-3.55 (m, 80H), 3.25 (br , 28H), 3.04 (br, 32H), 2.74 
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 (br , 28H), 1.73-1.68 (br , 74H), 1.40 (s, 144H), 1.15 (br, 28H), 1.03 (s, 36H); 13C NMR 
(125 MHz, CDCl3) δ 165.80, 164.78, 164.67, 156.10, 135.65, 133.69, 129.69, 127.73, 
78.99, 72.41, 72.30, 70.22, 70.15, 63.45, 61.64, 46.23, 43.22, 42.28, 40.69, 40.59, 37.18, 
36.94, 29.99, 29.75, 28.59, 27.78, 26.89, 19.24; MS (MALDI-TOF) calcd for 
C360H584Cl2N110O48Si4 7398.51, found 7399.18 (M+H)+. 
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 CHAPTER III 
POST-SYNTHETIC MANIPULATIONS OF A MELAMINE DENDRIMER AND 
IN VIVO BIODISTRIBUTION 
 
Introduction 
A variety of radiolabels are commonly used as molecular beacons due mostly to 
their sensitivity: 14C, 32P, 35S, iodine isotopes, and 3H.94 125I is one of the most effective 
markers used in biodistribution study.95 The radioactive iodine is highly sensitive, 
relatively safe (low γ energy emission). In addition, the target molecule can be easily 
labeled by radioactive iodine and stored for a while (60 day half-life). The 
radioiodination method developed by Bolton and Hunter utilizes 3-(4-
hydroxyphenyl)propionyl groups.96 The tyrosyl residue is very useful for iodination at 
the ortho position of the hydroxyl group. Positron emission tomography (PET) images 
can be also obtained with 120I (t1/2 = 1.4 h, β+ 56%) or 124I (t1/2 = 4.18 d, β+ 22%).94,97 
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Figure 3.1. Copper (II) complexing macrocyclic chelators. 
 
A variety of Radiometals are used in PET: 64Cu (t1/2 = 12.7 h, β+ 19%), 66Ga (t1/2 = 
9.5 h, β+ 56%), 86Y (t1/2 = 14.7 h, β+ 33%).98-100 Figure 3.1 shows macrocyclic chelators 
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 for Cu (II).100 These radiometal chelating ligands can be incorporated into dendrimers to 
non-invasively produce 2- or 3-dimensional images during in vivo biodistribution. 
Polyethylene glycol (PEG) is non-toxic, hydrophilic, and approved for clinical 
applications by FDA. The PEGylation of dendrimers is widely used to enhance the 
solubility in physiological conditions and to tailor the molecular size. 
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Figure 3.2. Potential post-synthetic manipulation of 1. 
 
 
Dendrimer 1 has potential for diverse biological applications due to its orthogonally 
reactive functional groups (Figure 3.2). In this study, we modify 1 by using two 
monochlorotriazine groups at the core and sixteen Boc-protected amine groups on the 
surface. The chlorine atoms are substituted with Bolton-Hunter type group or DOTA 
(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) ligand for biodisbution study 
and PET, respectively. After unmasking Boc groups, PEGylation is conducted by using 
the free amines. Potentially, the free hydroxyl and TBDPS ether groups can be further 
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 manipulated for drug conjugation and the attachment of targeting ligands. Preliminary 
biodistribution studies are also described here. 
 
Results and Discussion 
Post-Synthetic Manipulations of 1 
The synthesis of PEGylated dendrimers containing Bolton-Hunter groups is outlined 
in Scheme 3.1. The Bolton-Hunter type reagent is prepared in the treatment of BOC-
piperazine with 3-(4-hydroxyphenyl)propionic acid using PyBOP as a coupling agent in 
DMF.35,101 After the deprotection of the Boc group with trifluoroacetic acid (TFA), the 
nucleophilic Bolton-Hunter reagent is almost quantitatively incorporated to give 8. 
 
 
 
Scheme 3.1. Synthesis of PEGylated dendrimers with Bolton-Hunter reagent. 
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 The TBDPS ether groups of 8 is deprotected by using tetrabutylammonium fluoride 
(TBAF) in THF to afford 9, and then followed by treatment with TFA to produce 10. 
The Amines of 10 are pegylated with the different sizes of NHS-mPEG (MW 685, 2000 
and 5000 respectively). The PEGylated dendrimers 2, 3, and 4 are purified by dialysis in 
deionized water.  
       
Scheme 3.2. Synthesis of PEGylated dendrimers with DOTA. 
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The synthesis of PEGylated dendrimers containing DOTA groups is outlined in 
Scheme 3.2. Dendrimer 1 is reacted with the secondary amine of 4-aminomethyl 
piperidine (4-AMP) to give 11, and then followed by reaction with the NHS ester of a 
protected DOTA group to produce 12. The excess/decomposed DOTA-NHS ester 
reagents are removed by dialysis after the PEGylation step. Dendrimer 12 is treated 
with TBAF, and followed by reaction with TFA to give the deprotected dendrimer 
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 14. PEGylation is carried out to afford 5, 6, and 7. The small MW impurities 
including free PEG are removed by dialysis purification in deionized water. Table 
3.1 shows a library of dendrimers for biodistribution study. Dendrimers 2 to 7 have 
the range of MW about 11 to 82 kDa with the two types of reporting groups, 
Bolton-Hunter (BH) and DOTA.      
 
 
Table 3.1. A library of dendrimers (2-7) for biodistribution study. 
dendrimer MW (Da) (MALDI-TOF) reporting group solubilizing group 
2 11200 BH PEG 685 
3 30400 BH PEG 2000 
4 73400 BH PEG 5000 
5 11600 DOTA PEG 685 
6 28800 DOTA PEG 2000 
7 82100 DOTA PEG 5000 
 
 
MALDI-TOF MS is very useful to follow the synthesis of dendrimers (Figure 3.3). 
The mass ion peak of 8 containing BH groups was observed at 7794.11 [M + H]+ (the 
calculated exact mass: 7794.83). The mass ion of DOTA-dendrimer 12 was observed at 
8668.07 [M + H]+ (the calculated exact mass: 8663.52). The PEGylated dendrimers (2-7) 
are analyzed using GPC in 0.1 M NaNO3 (aq) with a refractive index (RI) detector 
(Figure 3.4). 
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Figure 3.3. MALDI-TOF mass spectra of 8 and 12. 
 
 
 
 
Figure 3.4. GPC traces of PEGylated dendrimers containing Bolton-Hunter (a) or 
DOTA groups (b). 
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 Preliminary In Vivo Biodistribution Studies  
Preliminary biodistribution studies were performed in collaboration with Dr. 
Xiankai Sun’s group at UT Southwestern Medical Center. BH-dendrimers 2, 3, and 4 are 
used to investigate biodistribution profiles that may depend on the molecular weight, 
composition, and structure of dendrimers. Radioiodination is conducted by using 
Iodogen (1,3,4,6-tetrachloro-3α,6α-diphenylglycouril), an effective oxidation reagent 
and Na125I in 0.1 N NaOH.102,103 After purification and analysis of 125I-labeled 
dendrimers, dendrimer solutions (100 μL, 6 μCi per mouse) are intravenously 
administered to healthy male BALB/c mice (four mice per group). The mice are 
sacrificed at the scheduled time points (30 min, 1 h, 4 h, 24 h, and 48 h post-injection). 
Blood, heart, lungs, liver, spleen, kidneys, fat, muscle, intestines, stomach, and thyroid 
are weighed, and the radioactivity of each organ is quantified. 
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Figure 3.5. Time-concentration plot of dendrimers in the blood. 
 
 
As shown in Figure 3.5, the percent injected dose per gram tissue (%ID/g) in the 
blood was higher with increasing MW of dendrimers: 2 (8.12 ± 1.64 %ID/g, MW 11200 
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 Da), 3 (16.95 ± 1.64 %ID/g, MW 30400 Da), and 4 (27.50 ± 1.73 %ID/g, MW 73400 
Da) at 48 h post-injection of 125I-labeled dendrimers, respectively. The pharmacokinetic 
data (Table 3.2) are obtained from the two-compartment open model (Figure 3.6).24,104 
The distribution half-lives (t1/2α) of dendrimers to other organs displayed similar patterns 
(2: 48.1 min, 3: 45.4 min, and 4: 52.1 min), while the elimination half-lives (t1/2β) and 
AUC0→∞ values were significantly increased in higher MW of dendrimers: 2 (1593.5 
min, 1188.9 %ID·h/g), 3 (2547.2 min, 2159.2 %ID·h/g), and 4 (6010.5 min, 5379.6 
%ID·h/g), respectively.  
 
 
Table 3.2. Pharmacokinetic data of the 125I-radiolabled dendrimers. 
Half-lives (min) AUC0→∞ Dendrimer 
t1/2α t1/2β (%ID·h/g)a 
2   48 1600 1200 
3   45 2500 2200 
4   52 6000 5400  
a AUC0→∞ equals the area under the %ID/g of blood curve from zero to infinite time.  
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Figure 3.6. Two-compartment open model kinetics following intravenous injection. 
 
 
Figure 3.7 shows the biodistribution results of dendrimers in the excretory organs: 
liver, lungs, spleen, and kidneys. Accumulation in the liver was observed with all the 
dendrimers. With decreasing the PEG chain length, the cellular uptake in the liver was 
increased presumably because the iodinated phenol groups at the core could be more 
easily recognized by receptors with less shielding.24 The biodistribution of dendrimers in 
other organs displayed similar patterns regardless of the MW. 
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Figure 3.7. Biodistribution data of 125I -labeled dendrimers. 
 
 
In addition, preliminary biodistribution studies were carried out with tumor-bearing 
mice. The dendrimer (MW ~17 kDa) used in this study was obtained from the reaction 
of 10 with activated PEG (750 Da) that was prepared by treating methoxypolyethylene 
glycol with 4-nitrophenyl chloroformate using pyridine in dichloromethane. Prostate 
cancer cells (PC-3-Luc) were injected subcutaneously into the right flank of each male 
nude mouse. 124I-labeled samples were prepared by using the same method described. As 
shown in coronal PET images (Figure 3.8), dendrimer accumulation in the tumor tissues 
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 slowly occurred, indicating the passive targeting via EPR effect. At 48 h post-injection 
of the dendrimer, the uptake ratios of tumor to muscle and blood were respectively 5.7 
and 3.3 (Figure 3.9). 
 
 
 
Figure 3.8. Coronal PET images of a 124I-labeled dendrimer in a tumor-bearing mouse. 
The injection dose was 727 μCi. The imaging acquisition time was 40 – 90 min. The 
imaging intensity is not on the same scale. 
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Figure 3.9. Post-PET biodistribution data of a 124I-labeled dendrimer (~17 kDa) in nude 
mice with PC-3-Luc xenografts at 48 h post-injection.
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 Conclusions 
We described post-synthetic manipulations and preliminary biodistribution studies 
using a versatile dendrimer with four orthogonally reactive groups. Reporting groups 
including BH and DOTA were incorporated by using monochlorotriazine groups. 
PEGylation was performed to improve the solubility in physiological conditions, 
tailoring the molecular size. Free hydroxyl and TBDPS ether groups can be potentially 
employed to other biological applications such as drug conjugation and the attachment 
of ligands. In preliminary biodistribution studies of 2, 3, and 4, higher MW dendrimers 
displayed longer circulation times in the blood. Slow tumor accumulation was observed 
even for a relatively small dendrimer (MW ~17 kDa) in mice bearing prostate cancer 
xenografts. The complete biodistribution studies using all the dendrimers (2-7) are being 
pursued.             
 
Experimental 
General Procedures 
NHS-mPEGs were purchased from Nektar Therapeutics and Quanta BioDesign. 
DOTA-mono-NHS-tris (t-Bu) ester was purchased from Macrocyclics. All other 
chemicals were purchased from Aldrich and Acros and used without further 
purification. All solvents were ACS grade and used without further purification. 
Dialysis membranes were purchased from Spectrum Laboratories, Inc. Size 
exclusion chromatography (SEC) was carried out using a Waters Delta 600 system 
and a Waters 2414 refractive index detector. A Suprema 10 micron GPC analytical 
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 column (1000 Å, 8 x 300 mm) was used with 0.1 M NaNO3 as the eluent and a flow rate 
of 1 mL/min. NMR spectra were recorded on a Varian Mercury 300 MHz or Inova 500 
MHz spectrometer in CDCl3, MeOH-d4, or CDCl3:MeOH-d4 (10:1). All mass spectral 
analyses were carried out by the Laboratory for Biological Mass Spectrometry at Texas 
A&M. 
Experimental Procedures 
Bolton-Hunter-BOC-piperazine. 1-BOC-piperazine (0.56 g, 3.0 mmol) and 
DIPEA (0.8 mL, 4.6 mmol) were added to a solution of 3-(4-hydroxyphenyl)propionic 
acid (0.50 g, 3.0 mmol) and PyBOP (1.72 g, 3.3 mmol) in DMF (10 mL). The solution 
was stirred for 12 h at room temperature.  The reaction mixture was poured into 50 mL 
of 0.5 M KHSO4 (aq) and extracted with ethyl acetate. The organic layer was washed 
with Sat. NaHCO3 (aq), dried over MgSO4, and then evaporated under vacuum. The 
crude product was purified by silica gel chromatography (ethyl acetate:hexane = 3:1) to 
afford a white hygroscopic solid (1.0 g, 99%). 1H NMR (300 MHz, CDCl3) δ 7.07 (dd, J 
= 6.5, 2.0, 2H,), 6.76 (dd, J = 6.5, 2.3, 2H), 3.58 (t, J = 5.3 Hz, 2H), 3.39-3.31 (m, 6H), 
2.90 (t, J = 7.8 Hz, 2H), 2.60 (t, J = 7.7 Hz, 2H), 1.46 (s, 9H); 13C NMR (75 MHz, 
CDCl3) δ 171.75, 155.24, 154.67, 131.67, 129.42, 115.50, 80.67, 45.47, 43.08, 41.53, 
35.31, 30.77, 28.36; MS (ESI-TOF) calcd for C18H26N2O4 334.19, found 335.19 (M+H)+.  
Bolton-Hunter-piperazine. Trifluoroacetic acid (10 mL) was added to an ice-bath 
cooled solution of the modified Bolton-Hunter reagent (1.0 g, 2.99 mmol) in 
dichloromethane (10 mL). The solution was warmed to room temperature and stirred for 
4 h. The solution was concentrated under vacuum to give a TFA salt. 1H NMR (300 
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 MHz, MeOH-d4) δ 7.04 (dd, J = 6.6, 2.1, 2H), 6.72 (dd, J = 6.5, 2.0, 2H), 3.78 (t, J = 5.0 
Hz, 2H), 3.65 (t, J = 5.0 Hz, 2H), 3.11 (t, J = 5.1 Hz, 2H), 2.97 (t, J = 5.0 Hz, 2H), 2.82 
(t, J = 7.5 Hz, 2H), 2.66 (t, J = 7.1 Hz, 2H); 13C NMR (75 MHz, MeOH-d4) δ 173.71, 
156.94, 132.63, 130.61, 116.29, 44.28, 43.64, 39.38, 35.41, 31.74; MS (ESI-TOF) calcd 
for C13H18N2O2 234.14, found 235.12 (M+H)+. 
Dendrimer 8. A solution of the modified Bolton-Hunter reagent salt (180 mg) in 
methanol (2 mL) was added to a solution of 1 (150 mg, 0.020 mmol) and DIPEA (0.4 
mL, 2.3 mmol) in dichloromethane (1 mL). The solution was stirred for 48 h at 50 oC 
and the solvent was then removed by reduced-pressure evaporation. The residue was 
dissolved in dichloromethane, washed with brine, dried over MgSO4 and evaporated 
under vacuum. The compound was purified by silica gel chromatography 
(dichloromethane:methanol = 10:1) to give 8 (155 mg, 98%) as a white solid. 1H NMR 
(500 MHz, CDCl3+MeOH-d4) δ 7.97 (dd, J = 7.8, 1.3, 16H), 7.68 (m, 24H), 7.32 (d, J = 
8.0, 4H), 7.04 (d, J = 7.5, 4H), 4.98 (br, 28H), 4.10-3.85 (m, 120H), 3.56 (br, 28H), 3.34 
(br, 32H), 3.17 (t, J = 7.3 Hz, 4H), 3.07 (br, 28H), 2.92 (br, 4H), 2.08-2.01 (br, 74H), 
1.71 (s, 144H), 1.46 (br, 28H), 1.33 (s, 36H); 13C NMR (125 MHz, CDCl3+MeOH-d4) δ 
171.74, 166.18, 165.82, 165.35, 164.81, 164.48, 156.34, 155.22, 135.41, 133.40, 131.40, 
129.51, 129.24, 127.51, 115.22, 79.08, 72.20, 72.09, 69.98, 69.78, 63.23, 61.16, 45.93, 
45.49, 43.05, 42.86, 42.53, 41.42, 40.36, 40.26, 37.08, 36.80, 35.21, 30.73, 30.06, 29.73, 
29.49, 29.18, 28.75, 28.23, 27.52, 26.60, 18.97; MS (MALDI-TOF) calcd for 
C386H618N114O52Si4 7794.83, found 7794.11 (M+H)+. 
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 Dendrimer 9. Dendrimer 8 (1.30 g, 0.167 mmol) was dissolved in THF (40 mL). 
1.0 M TBAF (1 mL, 1.0 mmol in THF) was added at 0 oC. The solution was warmed to 
room temperature and stirred under nitrogen overnight. The solvent was removed by 
reduced-pressure evaporation. The residue was dissolved in dichloromethane, washed 
with brine, dried over MgSO4 and evaporated under vacuum. The deprotected TBDPS 
was removed by silica gel chromatography (ethyl acetate to dichloromethane:methanol = 
8:1) to give 9 (1.05 g, 92%) as a white solid. MS (MALDI-TOF) calcd for 
C322H546N114O52 6842.36, found 6845.32 (M+H)+.  
Dendrimer 10. Trifluoroacetic acid (10 mL) was added to an ice-bath cooled 
solution of 9 (1.0 g) in dichloromethane (10 mL). The solution was warmed to room 
temperature and stirred for 24 h. The solution was concentrated under vacuum to give a 
TFA salt. The residue was dissolved in methanol and neutralized by adding 
triethylamine, and then evaporated under vacuum to afford 10 as a white solid. MS 
(MALDI-TOF) calcd for C242H418N114O20 5241.52, found 5244.63 (M+H)+. 
Dendrimer 11. A solution of 4-(aminomethyl)piperidine (0.50 g, 4.38 mmol) in 
methanol (4 mL) was added to a solution of 1 (0.35 g, 0.0473 mmol) in THF (16 mL). 
The solution was stirred for 24 h at room temperature, and then evaporated under 
vacuum. The residue was dissolved in dichloromethane, washed with brine, dried over 
MgSO4, and evaporated under vacuum. The crude product was purified by silica gel 
chromatography (dichloromethane:methanol = 7:1) to give 11 (0.35 g, 98%) as a white 
solid. 1H NMR (500 MHz, CDCl3) δ 7.67 (m, 16H), 7.38 (m, 24H), 4.70 (br, 32H), 3.79 
(t, J = 5.0 Hz, 8H), 3.74 (m , 16H), 3.57 (m, 80H), 3.27 (br , 28H), 3.05 (br, 32H), 2.76 
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 (br , 36H), 1.77-1.70 (br , 80H), 1.41 (s, 144H), 1.16 (br, 32H), 1.04 (s, 36H); 13C NMR 
(125 MHz, CDCl3+MeOH-d4) δ 165.56, 164.86, 164.10, 156.29, 134.95, 132.94, 129.09, 
127.07, 78.42, 71.73, 71.63, 69.54, 69.44, 62.87, 60.53, 45.46, 42.71, 39.91, 39.81, 
36.98, 36.60, 29.36, 27.53, 25.96, 18.41; MS (MALDI-TOF) calcd for 
C372H610N114O48Si4 7554.79, found 7576.12 (M+H)+. 
Dendrimer 12. DOTA-mono-NHS-tris (t-Bu) ester (100 mg, 0.123 mmol) in 
dichloromethane (2 mL) was added to a solution of 11 (130 mg, 0.0172 mmol) and 
DIPEA (0.1 mL, 0.58 mmol) in dichloromethane (5 mL). The solution was stirred 
under nitrogen for 24 h at room temperature. The reaction solution was poured into 15 
mL of 5% NaOH (aq) and extracted with dichloromethane. The organic layer was 
washed with brine, dried over MgSO4, and then evaporated under vacuum to give 12 as a 
white solid. MS (MALDI-TOF) calcd for C428H710N122O62Si4 8663.52, found 8668.07 
(M+H)+. 
Dendrimer 13. Dendrimer 12 (200 mg, 0.023 mmol) was dissolved in THF (10 mL). 
1.0 M TBAF (1 mL, 1.0 mmol in THF) was added at 0 oC. The solution was warmed to 
room temperature and stirred under nitrogen overnight. The solvent was removed by 
reduced-pressure evaporation. The residue was dissolved in dichloromethane, washed 
with brine, dried over MgSO4 and evaporated under vacuum. The deprotected TBDPS 
was removed by silica gel chromatography (ethyl acetate to dichloromethane:methanol = 
8:1) to give 13 (165 mg) as a white solid. MS (MALDI-TOF) calcd for C364H638N122O62 
7711.05, found 7752.79 (M+H)+.   
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 Dendrimer 14. Trifluoroacetic acid (5 mL) was added to an ice-bath cooled 
solution of 13 (150 mg) in dichloromethane (5 mL). The solution was warmed to room 
temperature and stirred for 24 h. The solution was concentrated under vacuum to give a 
TFA salt. The residue was dissolved in methanol and neutralized by adding 
triethylamine, and then evaporated under vacuum to give 14. MS (MALDI-TOF) calcd 
for C260H462N122O30 5773.84, found 5785.86 (M+H)+.  
Dendrimer 2. A solution of 10 (20 mg) and DIPEA (0.1 mL, 0.58 mmol) in DMF 
(1 mL) was added to a solution of NHS-mPEG (MW 685, 44 mg, 0.064 mmol) in 
dichloromethane (1 mL). The solution was stirred under nitrogen for 24 h at room 
temperature. The reaction solution was dialyzed to remove DMF against distilled water 
using a Specta/Por regenerated cellulose membrane (MWCO: 3.5 kDa) for 24 h, and 
then the solution was evaporated under vacuum. The residue was dissolved in deionized 
water and filtered. The filtrate was purified to remove low molecular weight impurities 
using a Spectra/Por cellulose ester membrane (MWCO: 10 kDa) in deionized water for 
48 h. The deionized water was changed every 12 h. The dialyzed solution was 
evaporated under vacuum to afford 2 as a colorless solid. The resulting compound was 
analyzed by size exclusion chromatography. MS (MALDI-TOF) calcd for 16 PEG 
species 14360.24, found 11184.91 (M+H)+. 
Dendrimer 3. A solution of 10 (12 mg) and DIPEA (0.1 mL, 0.58 mmol) in DMF 
(1 mL) was added to a solution of NHS-mPEG (MW 2000, 67 mg, 0.034 mmol) in 
dichloromethane (1 mL). The solution was stirred under nitrogen for 24 h at room 
temperature. The reaction solution was dialyzed to remove DMF against distilled water 
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 using a Specta/Por regenerated cellulose membrane (MWCO: 3.5 kDa) for 24 h, and 
then the solution was evaporated under vacuum. The residue was dissolved in deionized 
water and filtered. The filtrate was purified to remove low molecular weight impurities 
using a Spectra/Por cellulose ester membrane (MWCO: 10 kDa) in deionized water for 5 
days. The deionized water was changed every 12 h. The dialyzed solution was 
evaporated under vacuum to afford 3 as a white solid. The resulting compound was 
analyzed by size exclusion chromatography. MS (MALDI-TOF) calcd for 16 PEG 
species 35400.24, found 30423.46 (M+H)+. 
Dendrimer 4. A solution of 10 (12 mg) and DIPEA (0.1 mL, 0.58 mmol) in DMF 
(1 mL) was added to a solution of NHS-mPEG (MW 5000, 191 mg, 0.038 mmol) in 
dichloromethane (1 mL). The solution was stirred under nitrogen for 24 h at room 
temperature. The reaction solution was dialyzed to remove DMF against distilled water 
using a Specta/Por regenerated cellulose membrane (MWCO: 3.5 kDa) for 24 h, and 
then the solution was evaporated under vacuum. The residue was dissolved in deionized 
water and filtered. The filtrate was purified to remove low molecular weight impurities 
using a Spectra/Por cellulose ester membrane (MWCO: 50 kDa) in deionized water for 5 
days. The deionized water was changed every 12 h. The dialyzed solution was 
evaporated under vacuum to afford 4 as a white solid. The resulting compound was 
analyzed by size exclusion chromatography. MS (MALDI-TOF) calcd for 16 PEG 
species 83400.24, found 73408.90 (M+H)+. 
Dendrimer 5. A solution of 14 (20 mg) and DIPEA (0.1 mL, 0.58 mmol) in DMF 
(1 mL) was added to a solution of NHS-mPEG (MW 685, 44 mg, 0.064 mmol) in 
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 dichloromethane (1 mL). The solution was stirred under nitrogen for 24 h at room 
temperature. The reaction solution was dialyzed to remove DMF against distilled water 
using a Specta/Por regenerated cellulose membrane (MWCO: 3.5 kDa) for 24 h, and 
then the solution was evaporated under vacuum. The residue was dissolved in deionized 
water and filtered. The filtrate was purified to remove low molecular weight impurities 
using a Spectra/Por cellulose ester membrane (MWCO: 10 kDa) in deionized water for 
48 h. The deionized water was changed every 12 h. The dialyzed solution was 
evaporated under vacuum to afford 5 as a colorless solid. The resulting compound was 
analyzed by size exclusion chromatography. MS (MALDI-TOF) calcd for 16 PEG 
species 14892.56, found 11620.48 (M+H)+. 
Dendrimer 6. A solution of 14 (12 mg) and DIPEA (0.1 mL, 0.58 mmol) in DMF 
(1 mL) was added to a solution of NHS-mPEG (MW 2000, 67 mg, 0.034 mmol) in 
dichloromethane (1 mL). The solution was stirred under nitrogen for 24 h at room 
temperature. The reaction solution was dialyzed to remove DMF against distilled water 
using a Specta/Por regenerated cellulose membrane (MWCO: 3.5 kDa) for 24 h, and 
then the solution was evaporated under vacuum. The residue was dissolved in deionized 
water and filtered. The filtrate was purified to remove low molecular weight impurities 
using a Spectra/Por cellulose ester membrane (MWCO: 10 kDa) in deionized water for 5 
days. The deionized water was changed every 12 h. The dialyzed solution was 
evaporated under vacuum to afford 6 as a white solid. The resulting compound was 
analyzed by size exclusion chromatography. MS (MALDI-TOF) calcd for 16 PEG 
species 35932.56, found 28811.69 (M+H)+. 
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 Dendrimer 7. A solution of 14 (12 mg) and DIPEA (0.1 mL, 0.58 mmol) in DMF 
(1 mL) was added to a solution of NHS-mPEG (MW 5000, 191 mg, 0.038 mmol) in 
dichloromethane (1 mL). The solution was stirred under nitrogen for 24 h at room 
temperature. The reaction solution was dialyzed to remove DMF against distilled water 
using a Specta/Por regenerated cellulose membrane (MWCO: 3.5 kDa) for 24 h, and 
then the solution was evaporated under vacuum. The residue was dissolved in deionized 
water and filtered. The filtrate was purified to remove low molecular weight impurities 
using a Spectra/Por cellulose ester membrane (MWCO: 50 kDa) in deionized water for 5 
days. The deionized water was changed every 12 h. The dialyzed solution was 
evaporated under vacuum to afford 7 as a white solid. The resulting compound was 
analyzed by size exclusion chromatography. MS (MALDI-TOF) calcd for 16 PEG 
species 83932.56, found 82070.03 (M+H)+. 
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 CHAPTER IV 
SYNTHESIS AND CHARACTERIZATION OF A DENDRIMER BASED ON 
MELAMINE THAT RELEASES PACLITAXEL 
 
Introduction 
To date, various types of polymers have been investigated as drug delivery 
systems.14 Examples include grafts,51,52 stars,53 multivalent polymers,54 block 
copolymers,55 dendronized polymers,56 and dendrimers.10,13,24,37,79 Dendrimers are 
promising as drug-delivery vehicles by virtue of the following characteristics: 
multivalency; a well-defined and large globular structure; mono- or low polydispersity; 
amenability to postsynthetic manipulation. We, and others, believe that dendrimers may 
surmount some of the barriers to chemotherapy including poor solubility of some agents 
in physiological conditions, high systemic toxicity, poor bioavailability, and low stability. 
Through rational design, dendrimers might shift in vivo pharmacokinetics of the drug, 
accelerate cellular uptake, prolong plasma half-life, and even specifically target the 
diseased cells either actively (via ligands) or passively (via the enhanced permeability 
and retention (EPR) effect59,60 resulting from a leaky vasculature and the lack of 
lymphatic drainage in solid tumor tissues). 
We have chosen paclitaxel as our illustrative drug for four reasons. First, paclitaxel 
is a clinically relevant broad spectrum anticancer agent useful for treating tumors of the 
ovaries, breast, head and neck, lung, and AIDS-related Kaposi’s sarcoma.105 Second, it 
faces significant solubility challenges: its low solubility in water (< 0.1 μg/mL). Third, it 
51
 is amenable to synthetic manipulations (through esterification of the 2’-hydroxyl group) 
that provide a mechanism for conjugation and release.  Finally, the target molecules can 
be compared to a variety of delivery vehicles have been described including 
emulsions,106 micelles,107,108 liposomes,109 nanoparticles,110 and other dendrimers.111,112 
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The chemistry that we describe here is cartooned in Scheme 4.1. The methods and 
strategies employed in the synthesis of dendrimer derive from our previous efforts.32-45 
In summary, chlorine atoms on triazine rings are substituted in a stepwise fashion with 
amine nucleophiles. The benefits of this chemistry derive from the compositional 
diversity which is often a challenge in conventional polymers and other types of 
dendrimers. Dendrimer 1 possesses groups amenable to radioiodination.96  
Subsequently, 1 is reacted with a paclitaxel-containing group to provide 2.  PEGylation 
is achieved in two steps. Reaction of the poly(monochlorotriazine) dendrimer 2 with 4-
aminomethylpiperidine affords nucleophile for acylation with PEG groups that vary in 
size.  Here, two different PEG-NHS esters are employed to obtain products 4a and 4b.   
PEGylation is a convenient mechanism to convey biocompatibility and solubility to the 
hydrophobic triazine dendrimer while simultaneously allowing us to tailor its size, and 
52
 accordingly, its biodistribution times and fates. By employing PEG chains with 
molecular weights 2 and 5 kDa, by weight the vehicles 4a and 4b are 30% and 18% drug, 
52% and 71% PEG, and only 18% and 11% triazine dendrimer.  In addition to details 
of synthesis and characterization of these molecules, we also report on paclitaxel release. 
 
 
Scheme 4.1. Summary of the chemistries reported including paclitaxel conjugation and 
PEGylation. 
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Results and Discussion 
The results and discussion section are divided into five parts. The first three sections 
describe the synthesis of dendrimer 1, the paclitaxel-conjugate, and targets 2-4. The 
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 fourth part addresses characterization.  The fifth part describes release of paclitaxel 
from these conjugates. 
Part 1. Synthesis of Dendrimer 1   
Dendrimer 1 (Scheme 4.2) presents sixteen amines on the surface and two Bolton-
Hunter-like groups at the core. 
 
 
Scheme 4.2. Synthesis of a precursor dendrimer for drug conjugation.a 
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a Reagents and conditions: (a) cyanuric chloride, DIPEA, THF, 0 oC to rt, 24 h; then 
4-AMP, rt, 24 h; (b) cyanuric chloride, DIPEA, THF, 0 oC to rt, 24 h; then 4-AMP, rt, 24 
h; (c) cyanuric chloride, DIPEA, THF, 0 oC, 2 h; (d) piperazine, DIPEA, THF, CH3OH, 
0 oC to rt, 24 h; (e) modified Bolton-Hunter, DIPEA, CH2Cl2, CH3OH, 40 oC, 48 h; (f) 
TFA, CH2Cl2, CH3OH, 0 oC to rt, 12 h. 
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 The target was synthesized using a convergent route.113 Intermediate 5 is prepared 
in one pot by the reaction of cyanuric chloride with 2 equiv. of the Boc-protected 
triamine93 and subsequent reaction with the secondary amine of 4-aminomethyl 
piperidine (4-AMP). Elaboration of 5 to 6 proceeds in a similar way: cyanuric chloride is 
first reacted with 2 equiv. of 5, and followed by the addition of 4-AMP.  
Dichlorotriazine 7 was obtained by reacting 6 with cyanuric chloride. Dimerization of 7 
with piperazine yields 8. The radioiodination group (prepared as previously 
reported)35,101 was incorporated to give 9. Finally, the BOC groups of 9 were 
quantitatively removed using trifluoroacetic aicd (TFA). Overall, 1 is synthesized from 
the protected amine in 64% yield in six linear steps. 
Part 2. Synthesis of the Paclitaxel Conjugate  
Our modification strategy for the covalent attachment of paclitaxel to dendrimer 1 
follows the precedent esterification of the 2’-hydroxyl group.76,114 While both glutaric 
and succinic esters have been pursued, Safavy and coworkers114 reported that the glutaric 
ester-linked conjugates displayed better antitumor activity compared to the succinic 
ester-linked conjugate. Our strategy rests on the preparation of a dichlorotriazine 
modified with paclitaxel that could be used to react with the amines of 1, giving sixteen 
monochlorotriazines to be utilized for further modification.  The chemistry employed is 
outlined in Scheme 4.3. 
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 Scheme 4.3. Modifications of paclitaxela 
Ph NH
O
Ph O
O
O
AcO O OH
O
Ph
O
O
OAc
O
O
HN
HN
N
N
N
Cl
Cl
c
81%
a
80%
OH
H
10
12
13
RO
O
O
O
b
95%
RO
O
O
HN
H2N
11
Ph NH
O
Ph O
O
O
AcO O OH
O
Ph
O
O
OAc
O
O
OH
H
HO
R =
N
O
O
 
a Reagents and conditions: (a) SDPP, TEA, CH3CN, rt, 6 h; (b) 1,3-diaminopropane, 
TEA, CH2Cl2, 0 oC, 30 min; (c) cyanuric chloride, DIPEA, THF, 0 oC, 1 h. 
 
 
The conjugate is prepared in four steps in 60% overall yield. Paclitaxel is reacted 
with glutaric anhydride in the presence of pyridine to give 2’-glutarylpaclitaxel 10. 
Paclitaxel-NHS ester 11 is obtained by reaction of 10 with N-succinimidyl 
diphenylphosphate (SDPP).115 The paclitaxel-NHS ester is treated with excess of 1,3-
diaminopropane at low temperature to afford the amine 12. The linear, flexible diamine 
was chosen to reduce steric hindrance. Finally, the reaction of amine 12 with cyanuric 
chloride using DIPEA as a base yields the paclitaxel-dichlorotriazine 13.  
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Part 3. Synthesis of Dendrimers 2-4 
Scheme 4.1 describes the reaction of  dendrimer 1 with 13 to give 2. The resulting 
poly(monochlorotriazine) dendrimer undergoes nucleophilic aromatic substitution with 
4-AMP to afford 3. The sixteen primary amines of 3 were not fully pegylated due to 
steric hindrance. Accordingly, PEGylation with NHS-mPEGs 2 and 5 kDa gives 4a 
(MW ~46 kDa for 14 PEG chains) and 4b (MW ~77 kDa for 12 PEG chains), 
respectively. 
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Figure 4.1. 1H NMR assignment and integration of 2 in the expanded region 4.8 to 8.2 
ppm. The spectrum was obtained in CDCl3:MeOH-d4 (10:1). 
 
Part 4. Characterization  
With the exception of reactions involving 1-4, most reactions are readily monitored 
by thin layer chromatography. NMR spectroscopy and mass spectrometry are useful 
over the entire range of targets. Intermediates 5-13 provide satisfactory NMR and mass 
spectra data. Gel permeation chromatography (GPC) was used to follow the PEGylated 
dendrimers. The MALDI-TOF MS of the Boc-protected dendrimers, 5 to 9, was 
consistent with single chemical entities:  these spectra showed peaks derived from a 
single compound corresponding to [M + H]+, [M + Na]+, and [M + Ka]+ with ladder 
peaks from loss of BOC groups during the ionization. 
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 NMR spectroscopy was particularly useful to follow modification of paclitaxel. 
Figure 4.1 shows the assignment and integration of the spectrum confirm that up to 16 
molecules of paclitaxel are conjugated to 2. Obtaining consistent MALDI-TOF mass 
spectra from the hydrophobic dendrimer 2 was challenging: We believe those conditions 
that were optimal for ionization also led to fragmentation at the labile 2’-hydroxyl group.  
The spectrum in Figure 4.2 shows a good agreement between the calculated exact mass 
21038 and the observed mass 21114 (m/z). The ladder peaks occurring in the lower mass 
region can be attributed to either degraded analytes (loss of paclitaxel due to the labile 
ester link) from high laser intensity or incomplete reaction of the dichlorotriazine. 
15000 16500 18000 19500 21000 22500 24000
7
2: 21114 (m/z )
 
Figure 4.2. The MALDI-TOF spectrum of 2.  
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 The PEGylated paclitaxel-dendrimer conjugates 4a and 4b were analyzed with GPC, 
1H NMR, and MALDI-TOF MS. The PEGylated dendrimers are readily soluble in 
aqueous media allowing purification by dialysis. The dendrimers were analyzed using 
GPC in 0.1 M NaNO3 (aq) with a refractive index (RI) detector (Figure 4.3). 1H NMR 
spectroscopy was also used to characterize the drug conjugates. The spectra shown in 
Figure 4.4 display each peak of the aromatic rings of paclitaxel (7.25-8.09 ppm), the 
radioiodination group (respectively, 6.68 and 6.96 ppm for ortho and meta protons), and 
the PEG chains (~3.6 ppm). The molecular weight was determined by MALDI-TOF 
MS: 46100 Da for 4a and 77400 Da for 4b. This corresponds to macromolecules that are 
30% (4a) and 18 wt % (4b) paclitaxel. 
 
 
 
Figure 4.3. The analytical GPC chromatogram obtained using 0.1 M NaNO3 (aq) as an 
eluent with a RI detector: (a) before (dotted line) and after (solid line) dialysis 
purification of 4a; (b) GPC traces of 4a and 4b. 
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Figure 4.4. 1H NMR of the PEGylated paclitaxel conjugates 4a and 4b purified from 
dialysis. The spectra were obtained in CDCl3:MeOH-d4 (10:1). 
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 The polydispersity index (PDI) Mw/Mn was determined by GPC using THF as the 
eluent with polystyrene standards (Table 4.1). Both dendrimers showed very low PDIs 
(1.01-1.02). GPC analysis of dendrimer 4a in THF showed a peak corresponding to 
dimer (2M), which was not observed in aqueous eluent such as 0.1 M NaNO3. We are 
currently investigating the source of this dimerization. 
 
 
Table 4.1. Analysis and characterization of 4a and 4b. 
product MW (Da) (MALDI-TOF) Mn
a PDI (Mw/Mn)a 
wt % 
drug loading 
4a 46100 82200 (2M) 1.02 30% 
4b 77400 61300 1.01 18% 
a Determined by GPC in THF using polystyrene standards. 
 
 
Part 5. In Vitro Studies of Paclitaxel Release  
In vitro release of paclitaxel from 4a and 4b was evaluated using phosphate 
buffered saline (PBS) at the different pH (4.0, 5.5, and 7.4). The samples were prepared 
at the concentration of 0.2 mg/mL in microcentrifuge tubes and incubated at 37 oC with 
occasional vortexing. 
To quantify paclitaxel released, the samples were extracted with HPLC grade 
diethyl ether at the scheduled time respectively. After evaporating solvent, the sample 
was dissolved in 1 mL of ethanol. The amount of released paclitaxel was determined by 
measuring absorbance at 227 nm with the extinction coefficient ε= 3.13 x 104 M-1 cm-
1.116 Release of paclitaxel was confirmed by HPLC analysis (Figure 4.5) using a mobile 
phase of 60% acetonitrile and 40% water at a flow rate of 1 mL/min with Symmetry C18 
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 column (5 μm, 4.6 x 250 mm, Waters). The released palitaxel was eluted at 6.84 min and 
detected at 227 nm. Figure 4.5 shows the release of paclitaxel from the conjugates was 
faster at lower pH due to the acid-labile ester linkage. Though both drug conjugates 
showed the same pattern of pH-dependent release, 4b with longer PEG chains released 
the drug faster than 4a at the same pH. Overall, the rates of release were similar to those 
reported by Jing and coworkers in a micellar block copolymer.117 After 3 d incubation, 
the percent drug releases of 4a were respectively 25%, 19%, and 8% at the pH 4.0, 5.5, 
and 7.4, while those of 4b were respectively 33%, 24%, and 14%. 
 
 
Figure 4.5. Paclitaxel release from 4a and 4b in PBS buffers (pH 4.0, 5.5, and 7.4) at 37 
oC and a HPLC chromatogram showing paclitaxel released from the conjugates. 
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 Conclusions 
Here, we have described a drug-delivery vehicle, 2 that is installed with Bolton-
Hunter as biodistribution tag, paclitaxel with the ester linkage for controlled release, and 
monochlorotriazine groups to be PEGylated for aqueous solubilization and size tuning. 
The precursor dendrimer 1 was prepared at 64% overall yield from the bisprotected 
amine, and the modification of paclitaxel was proceeded in four steps with 60% overall 
yield. The analysis and characterization of 2 showed that the drug conjugate contained 
up to 16 molecules of paclitaxel indicating fully coupling of 1 with the modified drug. 
After PEGylation, we obtained two dendrimers 4a and 4b with about MW 46 and 77 
kDa respectively. In addition, the high paclitaxel payloads (up to 30 wt %) via the ester 
linkage can maximize the drug efficacy on the targeted cells, while reduce the toxicity 
during in vivo delivery of the drug. The in vitro drug release study of 4a and 4b revealed 
that paclitaxel was released faster at lower pH, indicating hydrolysis of the acid-labile 
ester link. Biological evaluation including in vivo biodistribution and toxicity studies 
will be performed in due course as well as the efficacy test with tumor models. 
 
Experimental 
General Procedures 
Paclitaxel (Taxol) was purchased from LC Laboratories or CEC. NHS-mPEGs were 
purchased from Nektar Therapeutics or Quanta BioDesign. All other chemicals were 
purchased from Aldrich and Acros and used without further purification. All 
solvents were ACS grade or HPLC grade and used without further purification. 
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 Dialysis membranes were purchased from Spectrum Laboratories, Inc. Size 
exclusion chromatography (SEC) was carried out using a Waters Delta 600 system 
and a Waters 2414 refractive index detector. A Suprema 10 micron GPC analytical 
column (1000 Å, 8 x 300 mm) was used with 0.1 M NaNO3 as the eluent and a flow rate 
of 1 mL/min. SEC analysis for the PDI was carried out using a Viscotek I-MBMMW-
3078 mixed bed column and a triple detector system including a Model VE3580 RI 
detector. Polystyrene standards were used for calibration, and THF was used as the 
eluent at a flow rate of 1mL/min. NMR spectra were recorded on a Varian Mercury 300 
MHz or Inova 500 MHz spectrometer in CDCl3, or CDCl3:MeOH-d4 (10:1). All mass 
spectral analyses were carried out by the Laboratory for Biological Mass Spectrometry 
at Texas A&M. 
Experimental Procedures 
2’-Glutarylpaclitaxel 10. Paclitaxel (0.50 g, 0.585 mmol) was added to a solution 
of glutaric anhydride (0.60 g, 5.25 mmol) in pyridine (7 mL). The solution was stirred 
under nitrogen for 4 h at room temperature, and then evaporated in vacuo. The residue 
was stirred in water (20 mL) for 30 min and extracted with dichloromethane. The 
organic layer was washed three times with brine, dried over MgSO4, and evaporated 
under vacuum. The crude product was purified by silica gel chromatography (washed 
with dichloromethane and eluted with ethyl acetate) to give a white solid (0.55 g, 97%). 
1H NMR (300 MHz, CDCl3) δ 8.14 (dd, J = 8.0, 1.5, 2H), 7.73 (dd, J = 8.4, 1.5, 2H), 
7.61 (t, J = 7.5 Hz, 1H), 7.53-7.31 (m, 10H), 6.29 (s, 1H), 6.26 (t, J = 9.0, 1H), 5.99 (dd, 
J = 9.3, 3.0, 1H), 5.68 (d, J = 7.2, 1H), 5.49 (d, J = 3.0, 1H), 4.98 (dd, J = 9.5, 2.1, 1H), 
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 4.44 (dd, J = 10.7, 6.5 1H), 4.31 (d, J = 8.7, 1H), 4.19 (d, J = 8.1, 1H), 3.81 (d, J = 7.2, 
1H), 2.56 (m, 1H), 2.47 (s, 3H), 2.45-2.39 (m, 3H), 2.34 (t, J = 7.5 Hz, 2H), 2.22 (s, 3H), 
2.17 (m, 1H), 1.94 (s, 3H), 1.91-1.84 (m, 3H), 1.67 (s, 3H), 1.23 (s, 3H), 1.13 (s, 3H); 
13C NMR (75 MHz, CDCl3) δ 203.95, 176.28, 172.05, 171.44, 170.02, 168.31, 167.71, 
167.12, 142.82, 136.96, 133.84, 133.71, 133.01, 132.19, 130.40, 129.35, 129.25, 128.90, 
128.85, 128.65, 127.32, 126.68, 84.58, 81.25, 79.15, 76.68, 75.75, 75.26, 74.36, 72.27, 
72.05, 58.63, 52.92, 45.72, 43.33, 35.68, 32.79, 32.42, 26.95, 22.84, 22.29, 20.98, 19.82, 
14.95, 9.74; MS (MALDI-TOF) calcd for C52H57NO17 967.36, found 990.56 (M+Na)+.. 
Paclitaxel-NHS ester 11. First, N-succinimidyl diphenylphosphate (SDPP) was 
prepared from the reaction of diphenyl chlorophosphate (2.68 g, 10 mmol), N-
hydroxysuccinimide (1.16 g, 10 mmol), and triethylamine (2.0 mL, 14 mmol) in 
dichloromethane (40 mL). The reaction solution was stirred under nitrogen for 2 h at 
room temperature, filtered, and evaporated. The residue was dissolved in ethyl acetate, 
washed three times with brine, dried over MgSO4, and then evaporated under vacuum to 
give SDPP (2.90 g, 84%).  A solution of SDPP (0.28 g, 0.81 mmol) in acetonitrile (10 
mL) was added to a solution of 10 (0.52 g, 0.54 mmol) and triethylamine (0.315 mL, 
2.21 mmol) in acetonitrile (10 mL).  The solution was stirred under nitrogen for 6 h at 
room temperature and concentrated under vacuum. The residue was purified by silica gel 
chromatography (ethyl acetate:hexane = 5:2) to give 11 as a white solid (0.46, 80%). 1H 
NMR (300 MHz, CDCl3) δ 8.14 (d, J = 6.9, 2H), 7.71 (d, J = 6.9, 2H), 7.61 (t, J = 7.5 
Hz, 1H), 7.54-7.33 (m, 10H), 6.30 (s, 1H), 6.28 (t, J = 8.4, 1H), 5.98 (dd, J = 9.3, 3.0, 
1H), 5.69 (d, J = 7.5, 1H), 5.48 (d, J = 3.0, 1H), 4.99 (d, J = 8.4, 1H), 4.45 (dd, J = 10.7, 
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 6.2 1H), 4.32 (d, J = 7.8, 1H), 4.21 (d, J = 8.7, 1H), 3.82 (d, J = 7.2, 1H), 2.91-2.51 (m, 
8H), 2.49 (s, 3H), 2.38 (t, J = 7.5 Hz, 2H), 2.23 (s, 3H), 2.21-2.02 (m, 3H), 1.95 (s, 3H), 
1.86 (m, 1H), 1.68(s, 3H), 1.24 (s, 3H), 1.14 (s, 3H); MS (MALDI-TOF) calcd for 
C56H60N2O19 1064.38, found 1087.14 (M+Na)+. 
Paclitaxel-diaminopropane 12. A solution of 11 (720 mg, 0.68 mmol) in 
dichloromethane (20 mL) was slowly added to an ice-bath cooled solution of 1,3-
diaminopropane (350 mg, 4.72 mmol)  and triethylamine (120 μL, 0.84 mmol) in 
dichloromethane (100 mL). The solution was stirred under nitrogen for 30 min at 0 oC. 
The solution was washed three times with brine, dried over MgSO4, and then evaporated 
in vacuo to give a white solid (660 mg, 95%). 1H NMR (300 MHz, CDCl3+MeOH-d4) δ 
8.09 (d, J = 6.9, 2H), 7.72 (d, J = 7.2, 2H), 7.58 (t, J = 7.2 Hz, 1H), 7.50-7.45 (m, 3H), 
7.40-7.35 (m, 6H), 7.29 (m, 1H), 6.31 (s, 1H), 6.12 (t, J = 8.4, 1H), 5.90 (d, J = 3.6, 1H), 
5.66 (d, J = 7.2, 1H), 5.40 (d, J = 3.9, 1H), 4.95 (d, J = 7.5, 1H), 4.34 (dd, J = 11.0, 6.8, 
1H), 4.27 (d, J = 8.4, 1H), 4.21 (d, J = 8.4, 1H), 3.76 (d, J = 6.9, 1H), 3.15 (t, J = 6.6 Hz, 
2H), 2.58 (t, J = 6.9, 2H), 2.51 (t, J = 7.2, 2H), 2.46-2.41 (m, 3H), 2.37 (s, 3H), 2.28 (m, 
1H), 2.17 (s, 3H), 2.10 (m, 1H), 1.90 (s, 3H), 1.88-1.79 (m, 3H), 1.64 (s, 3H), 1.54 (m, 
2H), 1.16 (s, 3H), 1.11 (s, 3H); 13C NMR (75 MHz, CDCl3) δ 203.88, 172.48, 172.29, 
171.32, 170.21, 168.77, 167.43, 167.02, 142.45, 137.16, 133.81, 133.78, 133.07, 132.08, 
130.38, 129.44, 129.21, 128.86, 128.73, 128.62, 127.45, 126.87, 84.58, 81.25, 79.13, 
76.59, 75.63, 75.20, 74.28, 72.17, 71.99, 58.55, 53.12, 46.23, 45.74, 43.38, 37.93, 35.85, 
35.73, 35.20, 33.04, 26.95, 22.87, 22.42, 21.15, 21.01, 14.93, 9.84; MS (MALDI-TOF) 
calcd for C55H65N3O16 1023.44, found 1024.21 (M+H)+. 
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 Paclitaxel-dichlorotriazine 13. A solution of cyanuric chloride (135 mg, 0.73 
mmol) in THF (5 mL) was added to an ice-bath cooled solution of 12 (650 mg, 0.64 
mmol) and DIPEA (250 μL, 1.42 mmol) in THF. The solution was stirred for 1 h at 0 oC 
and concentrated in vacuo. The residue was dissolved in dichloromethane, washed three 
times with brine, dried over MgSO4, and then evaporated. The crude product was 
purified by silica gel chromatography (ethyl acetate:dichloromethane:methanol = 8:8:1) 
to give a white solid (610 mg, 81%). 1H NMR (300 MHz, CDCl3+MeOH-d4) δ 8.10 (d, J 
= 7.2, 2H), 7.75 (d, J = 6.9, 2H), 7.61 (t, J = 7.5 Hz, 1H), 7.53-7.37 (m, 9H), 7.29 (m, 
1H), 6.34 (s, 1H), 6.14 (t, J = 8.7, 1H), 5.91 (dd, J = 9.2, 4.1, 1H), 5.67 (d, J = 7.2, 1H), 
5.42 (d, J = 4.2, 1H), 4.96 (d, J = 7.5, 1H), 4.35 (dd, J = 10.8, 6.6, 1H), 4.28 (d, J = 8.1, 
1H), 4.21 (d, J = 8.4, 1H), 3.78 (d, J = 7.2, 1H), 3.38 (t, J = 6.6 Hz, 2H), 3.18 (t, J = 6.6 
Hz, 2H), 2.52-2.44 (m, 3H), 2.39 (s, 3H), 2.31-2.22 (m, 3H), 2.18 (s, 3H), 2.07 (m, 1H), 
1.93 (s, 3H), 1.89 (m, 3H), 1.70 (m, 2H), 1.66 (s, 3H), 1.17 (s, 3H), 1.14 (s, 3H); 13C 
NMR (75 MHz, CDCl3+MeOH-d4) δ 203.81, 173.59, 172.34, 170.78, 170.17, 169.82, 
169.28, 169.01, 168.77, 166.41, 165.44, 141.48, 136.54, 136.51, 133.68, 133.35, 133.04, 
131.75, 129.90, 129.38, 128.83, 128.38, 128.34, 127.11, 126.72, 84.42, 80.90, 77.71, 
76.33, 75.48, 74.78, 74.03, 71.84, 71.20, 57.97, 53.02, 45.78, 43.10, 38.11, 36.06, 35.67, 
35.05, 34.54, 32.58, 28.35, 26.20, 22.32, 21.67, 20.66, 20.49, 14.21, 9.45; MS (MALDI-
TOF) calcd for C58H64Cl2N6O16 1170.38, found 1193.00 (M+Na)+.  
Intermediate 5.  A solution of cyanuric chloride (1.24 g, 6.72 mmol) in THF (20 
mL) was added to an ice-bath cooled solution of BisBoctriamine (4.50 g, 13.6 mmol) 
and DIPEA (4.4 mL, 24.9 mmol) in THF (50 mL). The solution was stirred for 1h at 0 
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 oC, warmed to room temperature, and then reacted for 24 h. After the addition of 4-
aminomethyl piperidine (3.0 mL, 26.3 mmol), the solution was stirred for an additional 
24 h at room temperature and evaporated under vacuum. The residue was dissolved in 
dichloromethane, washed with brine, dried over MgSO4, and then evaporated under 
vacuum. The crude product was purified by silica gel chromatography 
(dichloromethane:methanol = 8:1 with 1% NH4OH) to give 5 (5.30 g, 93%) as a white 
solid. 1H NMR (500 MHz, CDCl3+MeOH-d4) δ 4.69 (d, J = 13.0, 2H), 3.51 (br, 8H), 
3.04 (br, 8H), 2.78 (t, J = 11.8 Hz, 2H), 2.56 (d, J = 6.5, 2H), 1.72 (br, 10H), 1.58 (br, 
1H), 1.39 (s, 36H), 1.11 (ddd, J = 24.8, 12.5, 4.0, 2H); 13C NMR (75 MHz, CDCl3) δ 
165.48, 164.85, 156.09, 79.01, 47.91, 43.40, 43.14, 42.41, 39.70, 38.10, 37.19, 29.78, 
28.55, 27.97; MS (MALDI-TOF) calcd for C41H77N11O8 851.60, found 852.55 (M+H)+. 
Intermediate 6.  A solution of cyanuric chloride (379 mg, 2.05 mmol) in THF (20 
mL) was added to an ice-bath cooled solution of 5 (3.50 g, 4.11 mmol) and DIPEA (1.4 
mL, 7.92 mmol) in THF (50 mL). The solution was stirred for 1 h at 0 oC, warmed to 
room temperature, and then reacted for 24 h. After the addition of 4-aminomethyl 
piperidine (3.0 mL, 26.3 mmol), the solution was stirred for an additional 24 h at room 
temperature and evaporated under vacuum. The residue was dissolved in 
dichloromethane, washed with brine, dried over MgSO4, and evaporated under vacuum.  
The crude product was purified by silica gel chromatography 
(dichloromethane:methanol = 8:1 with 1% NH4OH) to give 6 (3.60 g, 93% ) as a white 
solid. 1H NMR (500 MHz, CDCl3+MeOH-d4) δ 4.67 (d, J = 12.5, 6H), 3.49 (br, 16H), 
3.23 (br, 4H), 3.04 (br, 16H), 2.76 (m, 6H), 2.56 (d, J = 6.5, 2H), 1.74 (br, 24H), 1.60 (br, 
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 1H), 1.39 (s, 72H), 1.12 (m, 6H); 13C NMR (75 MHz, CDCl3) δ 165.55, 164.92, 156.19, 
79.15, 46.20, 43.40, 42.64, 38.18, 37.39, 29.98, 29.77, 28.63, 28.11; MS (MALDI-TOF) 
calcd for C91H165N27O16 1892.29, found 1892.98 (M+H)+. 
Intermediate 7.  A solution of cyanuric chloride (330 mg, 1.79 mmol) in THF (10 
mL) was added to an ice-bath cooled solution of 6 (2.91 g, 1.54 mmol) and DIPEA (0.5 
mL, 2.80 mmol) in THF (50 mL). The solution was stirred for 3 h at 0 oC and evaporated 
under vacuum. The residue was dissolved in dichloromethane, washed with brine, dried 
over MgSO4, and evaporated under vacuum.  The crude product was purified by silica 
gel chromatography (ethyl acetate:hexane = 3:1) to give 7 (2.84 g, 90% ) as a white solid. 
1H NMR (500 MHz, CDCl3+MeOH-d4) δ 4.67 (d, J = 12.0, 6H), 3.49 (br, 16H), 3.31 (br, 
2H), 3.24 (br, 4H), 3.05 (br, 16H), 2.78 (t, J = 12.0, 6H), 1.74 (br, 25H), 1.39 (s, 72H), 
1.16 (br, 6H); 13C NMR (75 MHz, CDCl3) δ 171.05, 170.00, 166.29, 165.58, 164.93, 
156.18, 79.15, 46.31, 43.38, 42.76, 38.21, 37.50, 36.34, 29.97, 29.57, 28.63, 28.21; MS 
(MALDI-TOF) calcd for C94H164Cl2N30O16 2039.23, found 2040.13 (M+H)+. 
Intermediate 8. A solution of piperazine (30.4 mg, 0.353 mmol) and DIPEA (300 
μL, 1.70 mmol) in methanol (3 mL) was added dropwise to an ice-bath cooled solution 
of 7 (1.44 g, 0.707 mmol) in THF (15 mL).  The solution was warmed to room 
temperature, stirred for 24 hr, and then evaporated under vacuum.  The residue was 
dissolved in dichloromethane, washed with brine, dried over MgSO4, and evaporated 
under vacuum.  The crude product was purified by silica gel chromatography 
(dichloromethane:methanol = 9:1) to give 8 (1.30 g, 90%) as a white solid. 1H NMR 
(300 MHz, CDCl3+MeOH-d4) δ 4.67 (d, J = 12.0, 12H), 3.82 (br, 8H), 3.49 (br, 32H), 
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 3.25 (br, 12H), 3.04 (br, 32H), 2.78 (t, J = 11.9, 12H), 1.73 (br, 50H), 1.39 (s, 144H), 
1.17 (br, 12H); 13C NMR (75 MHz, CDCl3+MeOH-d4) δ 169.58, 168.62, 165.22, 164.67, 
164.24, 156.42, 79.04, 45.95, 43.09, 42.63, 38.88, 37.81, 37.07, 36.76, 29.70, 28.85, 
28.15, 27.74; MS (MALDI-TOF) calcd for C192H336Cl2N62O32 4092.59, found 4093.96 
(M+H)+. 
Dendrimer 9. A solution of the modified Bolton-Hunter reagent salt (300 mg) in 
methanol (2 mL) was added to a solution of 8 (300 mg, 0.073 mmol) and DIPEA (0.4 
mL, 2.3 mmol) in dichloromethane (1 mL). The solution was stirred for 48 h at 40 oC 
and the solvent was then removed by reduced-pressure evaporation. The residue was 
dissolved in dichloromethane, washed with brine, dried over MgSO4 and evaporated 
under vacuum. The crude compound was purified by silica gel chromatography (ethyl 
acetate:dichloromethane:methanol = 10:10:1) to give 9 (300 mg, 92%) as a white solid. 
1H NMR (300 MHz, CDCl3+MeOH-d4) δ 7.00 (d, J = 8.7, 4H), 6.72 (d, J = 8.4, 4H), 
4.68 (br, 12H), 3.77 (br, 24H), 3.49 (br, 32H), 3.30 (br, 12H), 3.03 (br, 32H), 2.86-2.73 
(m, 16H), 2.60 (t, J = 7.4, 4H), 1.71 (br, 50H), 1.38 (s, 144H), 1.17 (br, 12H); 13C NMR 
(75 MHz, CDCl3+MeOH-d4) δ 171.85, 166.21, 165.24, 164.85, 164.70, 156.46, 155.20, 
131.36, 129.21, 115.19, 79.08, 46.06, 45.58, 43.42, 42.99, 41.40, 37.85, 37.14, 36.39, 
35.21, 30.68, 29.68, 28.95, 28.19, 27.78; MS (MALDI-TOF) calcd for C218H370N66O36 
4488.92, found 4491.07 (M+H)+. 
Dendrimer 1. Trifluoroacetic acid (3 mL) was added to an ice-bath cooled solution 
of 9 (300 mg, 0.067 mmol) in dichloromethane (3 mL).  Methanol (1 mL) was added to 
the solution. The solution was warmed to room temperature and stirred for 12 hr.  The 
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 solution was concentrated under vacuum to give a TFA salt and neutralized with 
triethylamine. MS (MALDI-TOF) calcd for C138H242N66O4 2888.08, found 2889.19 
(M+H)+. 
Dendrimer 2. A solution of 1 (80 mg, 2.77*10-2 mmol) in water (3 mL) and THF (7 
mL) was slowly added to a solution of 13 (660 mg, 0.563 mmol) and DIPEA (200 μL, 
1.13 mmol) in THF (20 mL). The solution was stirred for 48 h at room temperature and 
evaporated under vacuum. The residue was dissolved in dichloromethane, washed with 
brine, dried over MgSO4, and evaporated under vacuum. The crude product was purified 
by silica gel chromatography (washed with ethyl acetate:dichloromethane:methanol = 
8:8:1 and eluted with dichloromethane:methanol = 8:1) to give 2 (468 mg, 80%) as a 
white solid. The excess or unreacted paclitaxel-dichlorotriazine was recovered from the 
purification and reused. 1H NMR (500 MHz, CDCl3+MeOH-d4) δ 8.08 (d, J = 7.5, 32H), 
7.72 (br, 32H), 7.57 (t, J = 7.3, 16H), 7.49-7.34 (m, 144H), 7.27 (br, 16H), 6.96 (d, J = 
7.5, 4H), 6.68 (d, J = 6.5, 4H), 6.31 (s, 16H), 6.12 (br, 16H), 5.89 (br, 16H), 5.65 (d, J = 
6.5, 16H), 5.40 (d, J = 3.0, 16H), 4.93 (d, J = 9.0, 16H), 4.61 (br, 12H), 4.34 (br, 16H), 
4.25 (d, J = 8.0, 16H), 4.19 (d, J = 8.0, 16H), 3.75 (d, J = 6.5, 16H), 3.62-3.13 (br m, 
164H), 2.76 (br, 16H), 2.56 (br, 4H), 2.48-2.37 (br m, 96H), 2.27-2.06 (br m, 112H), 
1.90-1.64 (br m, 226H), 1.19 (br, 12H), 1.15 (s, 48H), 1.11 (s, 48H); 13C NMR (125 
MHz, CDCl3+MeOH-d4) δ 203.90, 173.27, 172.43, 171.81, 170.88, 169.91, 168.82, 
165.26, 164.87, 141.70, 141.61, 136.67, 133.75, 133.45, 133.17, 131.84, 130.03, 129.49, 
129.29, 128.94, 128.51, 128.44, 127.22, 126.83, 115.27, 84.49, 81.04, 77.88, 76.44, 
75.60, 74.91, 74.13, 71.95, 71.38, 58.13, 53.09, 45.85, 43.21, 38.00, 37.49, 36.62, 35.79, 
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 35.21, 34.88, 32.74, 29.57, 29.26, 28.72, 27.23, 26.39, 22.47, 21.85, 20.80, 20.74, 20.65, 
14.38, 9.61; MS (MALDI-TOF) calcd for C1066H1250Cl16N162O260 21038.46, found 
21113.59 (M+Na)+. 
Dendrimer 3. A solution of 4-aminomethylpiperidine (23 μL, 0.20 mmol) in THF 
(5 mL) was added to an ice-bath coold solution of 2 (60 mg, 2.85*10-3 mmol) in THF 
(10 mL). The solution was warmed to room temperature and stirred under nitrogen for 
16 h. After the dilution with chloroform (20 mL), the solution was washed two times 
with brine, dried over MgSO4, and evaporated under vacuum to give 3 (60 mg, 94%) as 
a white solid. MS (MALDI-TOF) calcd for C1162H1458N194O260 22288.68, found 
22302.19 (M+H)+. 
Dendrimer 4a. A solution of NHS-mPEG (MW 2 kDa, 146 mg, 7.3*10-2 mmol) in 
dichloromethane (5 mL) was added to a solution of 3 (68 mg, 3.1*10-3 mmol) and 
DIPEA (30 μL, 0.17 mmol) in dichloromethane (5mL) and THF (10 mL). The solution 
was stirred under nitrogen for 24 h at room temperature and concentrated in vacuo. The 
residue was dissolved in deionized water and filtered. The filtrate was purified to remove 
low molecular weight impurities using a Spectra/Por cellulose ester membrane (MWCO: 
25 kDa) in deionized water for 10 days. The deionized water was changed every 12 h. 
The dialyzed solution was evaporated under vacuum to afford 4a as a white solid. The 
resulting compound was analyzed by size exclusion chromatography. MS (MALDI-TOF) 
PEGylated, found 46100.67 (M+H)+. 
Dendrimer 4b. A solution of NHS-mPEG (MW 5 kDa, 280 mg, 5.6*10-2 mmol) in 
dichloromethane (5 mL) was added to a solution of 3 (60 mg, 2.7*10-3 mmol) and 
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 DIPEA (22 μL, 0.13 mmol) in dichloromethane (5mL) and THF (10 mL). The solution 
was stirred under nitrogen for 24 h at room temperature and concentrated in vacuo. The 
residue was dissolved in deionized water and filtered. The filtrate was purified to remove 
low molecular weight impurities using a Spectra/Por cellulose ester membrane (MWCO: 
50 kDa) in deionized water for 10 days. The deionized water was changed every 12 h. 
The dialyzed solution was evaporated under vacuum to afford 4b as a white solid. The 
resulting compound was analyzed by size exclusion chromatography. MS (MALDI-TOF) 
PEGylated, found 77376.79 (M+H)+. 
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 CHAPTER V 
SUMMARY 
 
Dendrimers have unique and promising characteristics to be used as drug delivery 
vehicles: multivalency, functional diversity, a well-defined globular structure, and 
mono- or low polydispersity. Here, dendrimers based on melamine were investigated to 
develop potent drug delivery system. 
First, a versatile dendrimer with four orthogonally reactive groups was synthesized: 
two monochlorotriazine groups at the core, four free hydroxyl, four TBDPS ether, and 
sixteen BOC groups on the surface. The multiple functional groups can be utilized for 
diverse biological applications including PEGylation, radio-labeling, the attachment of 
targeting ligands, and drug conjugation. 
Second, post-synthetic manipulations of the dendrimer above were carried out, and 
followed by preliminary biodistribution studies. By using monochlorotriazine groups, 
the reporting groups, Bolton-Hunter and DOTA were incorporated into the dendrimer. 
The in vivo biodistribution of dendrimers can be evaluated by employing either 
radioactive iodines or metals. PEGylation provided the enhanced solubility in 
physiological conditions and tailored the molecular size. We also investigated in vivo 
biodistribution of these modified triazine dendrimers. As expected, dendrimers with 
longer PEG chains displayed a prolonged plasma circulation time, which was a 
promising property to passively target the diseased tissues via the EPR effect. High 
uptake by tumor tissues was found for this melamine dendrimer in tumor-bearing mice. 
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 Finally, a dendrimer including Bolton-Hunter groups, monochlorotriazine groups 
for PEGylation, and the anticancer agent paclitaxel groups was designed and synthesized. 
This drug delivery vehicle contains up to 30 wt % paclitaxel (16 molecules per 
dendrimer) via acid-labile ester linkage. The in vitro paclitaxel release studies displayed 
that the drug was released faster at lower pH. The complete biological evaluation of the 
dendritic drug carriers has been being pursued. 
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Figure A.1a. The ESI-TOF mass spectrum of 2. 
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Figure A.1b. The 1H NMR spectrum of 2. 
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Figure A.1c. The 13C NMR spectrum of 2. 
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Figure A.2a. The ESI-TOF mass spectrum of 3. 
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Figure A.2b. The 1H NMR spectrum of 3. 
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Figure A.2c. The 13C NMR spectrum of 3. 
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Figure A.3a. The MALDI-TOF mass spectrum of 4. 
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Figure A.3b. The 1H NMR spectrum of 4. 
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Figure A.3c. The 13C NMR spectrum of 4. 
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Figure A.4a. The MALDI-TOF mass spectrum of 5. 
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Figure A.4b. The 1H NMR spectrum of 5. 
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Figure A.4c. The 13C NMR spectrum of 5. 
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Figure A.5a. The ESI-TOF mass spectrum of 6. 
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Figure A.5b. The 1H NMR spectrum of 6. 
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Figure A.5c. The 13C NMR spectrum of 6. 
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Figure A.6a. The MALDI-TOF mass spectrum of 7. 
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Figure A.6b. The 1H NMR spectrum of 7. 
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Figure A.6c. The 13C NMR spectrum of 7. 
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Figure A.7a. The MALDI-TOF mass spectrum of 8. 
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Figure A.7b. The 1H NMR spectrum of 8. 
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Figure A.7c. The 13C NMR spectrum of 8. 
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Figure A.8a. The MALDI-TOF mass spectrum of 9. 
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Figure A.8b. The 1H NMR spectrum of 9. 
R
N
N
N
ClCl
9
N
N
N
N
N
N
NN
NH
NH
N
N
NH
N
N
N
HN
N(CH2CH2CH2NHBoc)2
O O-TBDPS
N
N
N
HN
N(CH2CH2CH2NHBoc)2
O OH
N
N
N N
HN
NH
N
N
N
N
N
NH
(BocHNH2CH2CH2C)2N
OHO
N
N
N
NH
(BocHNH2CH2CH2C)2N
OTBDPS-O
HN
NH
R =
107
  
 
 
Figure A.8c. The 13C NMR spectrum of 9. 
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Figure A.9a. The MALDI-TOF mass spectrum of 1. 
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Figure A.9b. The 1H NMR spectrum of 1. 
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Figure A.9c. The 13C NMR spectrum of 1. 
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Figure B.1a. The ESI-TOF mass spectrum of BH-BOC-piperazine. 
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Figure B.1b. The 1H NMR spectrum of BH-BOC-piperazine. 
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Figure B.1c. The 13C NMR spectrum of BH-BOC-piperazine. 
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Figure B.2a. The ESI-TOF mass spectrum of BH-piperazine. 
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Figure B.2b. The 1H NMR spectrum of BH-piperazine. 
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Figure B.2c. The 13C NMR spectrum of BH-piperazine. 
HO N
NH
O
118
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B.3a. The MALDI-TOF mass spectrum of 8. 
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Figure B.3b. The 1H NMR spectrum of 8. 
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Figure B.3c. The 13C NMR spectrum of 8. 
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Figure B.4a. The MALDI-TOF mass spectrum of 9. 
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Figure B.5a. The MALDI-TOF mass spectrum of 10. 
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Figure B.6a. The MALDI-TOF mass spectrum of 11. 
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Figure B.6b. The 1H NMR spectrum of 11. 
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Figure B.6c. The 13C NMR spectrum of 11. 
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Figure B.7a. The MALDI-TOF mass spectrum of 12. 
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Figure B.8a. The MALDI-TOF mass spectrum of 13. 
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Figure B.9a. The MALDI-TOF mass spectrum of 14. 
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Figure B.10a. The MALDI-TOF mass spectrum of 2. 
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Figure B.11a. The MALDI-TOF mass spectrum of 3. 
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Figure B.12a. The MALDI-TOF mass spectrum of 4. 
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Figure B.13a. The MALDI-TOF mass spectrum of 5. 
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Figure B.14a. The MALDI-TOF mass spectrum of 6. 
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Figure B.15a. The MALDI-TOF mass spectrum of 7. 
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Figure C.1a. The MALDI-TOF mass spectrum of 10. 
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Figure C.1b. The 1H NMR spectrum of 10. 
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Figure C.1c. The 13C NMR spectrum of 10. 
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Figure C.2a. The MALDI-TOF mass spectrum of 11. 
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Figure C.2b. The 1H NMR spectrum of 11. 
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Figure C.3a. The MALDI-TOF mass spectrum of 12. 
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Figure C.3b. The 1H NMR spectrum of 12. 
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Figure C.3c. The 13C NMR spectrum of 12. 
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Figure C.4a. The MALDI-TOF mass spectrum of 13. 
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Figure C.4b. The 1H NMR spectrum of 13. 
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Figure C.4c. The 13C NMR spectrum of 13. 
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Figure C.5a. The MALDI-TOF mass spectrum of 5. 
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Figure C.5b. The 1H NMR spectrum of 5. 
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Figure C.5c. The 13C NMR spectrum of 5. 
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Figure C.6a. The MALDI-TOF mass spectrum of 6. 
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Figure C.6b. The 1H NMR spectrum of 6. 
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Figure C.6c. The 13C NMR spectrum of 6. 
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Figure C.7a. The MALDI-TOF mass spectrum of 7. 
N N
N NN
N
H
NO
NHHN
O
H
N O
O
O
O
OO
NH
N
N
N
N
N N
N
N
N
NH
O
HN
H
N O
NH
O
O
O
O
O
O
N
H
N
NHN
N N
Cl
Cl
7
154
  
 
 
Figure C.7b. The 1H NMR spectrum of 7. 
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Figure C.7c. The 13C NMR spectrum of 7. 
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Figure C.8a. The MALDI-TOF mass spectrum of 8. 
N
N
N
N
N
N
HN
O
NH
NH
O
HN
O
O
O
O
O
O
HN
N
N
N
N
N
N
N
N
N
NH
O
N
H
HN
O
NH
O
O
O
O
O
O
NH
N
NH
N
N
N
N
Cl
N
N
N
N
N
N
N
NH
O
HN
HN
O
NH
O
O
O
O
O
O
NH
N
N
N
N
N
N
N
N
N
HN
O
H
N
NH
O
HN
O
O
O
O
O
O
HN
N
HN
N
N
N
Cl
8
157
  
 
 
Figure C.8b. The 1H NMR spectrum of 8. 
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Figure C.8c. The 13C NMR spectrum of 8. 
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Figure C.9a. The MALDI-TOF mass spectrum of 9. 
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Figure C.9b. The 1H NMR spectrum of 9. 
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Figure C.9c. The 13C NMR spectrum of 9. 
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Figure C.10a. The MALDI-TOF mass spectrum of 1. 
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Figure C.11a. The MALDI-TOF mass spectrum of 2. 
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Figure C.11b. The 1H NMR spectrum of 2. 
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Figure C.11c. The 13C NMR spectrum of 2. 
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Figure C.12a. The MALDI-TOF mass spectrum of 3. 
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Figure C.13a. The MALDI-TOF mass spectrum of 4a. 
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Figure C.13b. The 1H NMR spectrum of 4a. 
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Figure C.14a. The MALDI-TOF mass spectrum of 4b. 
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Figure C.14b. The 1H NMR spectrum of 4b.
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